Michael A. Davies, M.D., Ph.D.

Peer-Reviewed Articles

1. Ferguson SD, Bindal S, Bassett RL, Haydu LE, McCutcheon IE, Heimberger AB, Li J, O'Brien BJ, Guha-Thakurta N, Tetzlaff MT, Tawbi H, Davies MA, Glitza IC. Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD). J Neurooncol 142(3):499-509, 2019. e-Pub 2019. PMID: 30847840.
2. Fischer GM, Jalali A, Kircher DA, Lee WC, McQuade JL, Haydu LE, Joon AY, Reuben A, de Macedo MP, Carapeto FCL, Yang C, Srivastava A, Ambati CR, Sreekumar A, Hudgens CW, Knighton B, Deng W, Ferguson SD, Tawbi HA, Glitza IC, Gershenwald JE, Vashisht Gopal YN, Hwu P, Huse JT, Wargo JA, Futreal PA, Putluri N, Lazar AJ, DeBerardinis RJ, Marszalek JR, Zhang J, Holmen SL, Tetzlaff MT, Davies MA. Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. Cancer Discov 9(5):628-645, 2019. e-Pub 2019. PMID: 30787016.
3. Eroglu Z, Holmen SL, Chen Q, Khushalani NI, Amaravadi R, Thomas R, Ahmed KA, Tawbi H, Chandra S, Markowitz J, Smalley I, Liu JKC, Chen YA, Najjar YG, Karreth FA, Abate-Daga D, Glitza IC, Sosman JA, Sondak VK, Bosenberg M, Herlyn M, Atkins MB, Kluger H, Margolin K, Forsyth PA, Davies MA, Smalley KSM. Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities. Pigment Cell Melanoma Res 32(3):458-469, 2019. e-Pub 2019. PMID: 30712316.
4. Kluger HM, Margolin KA, Davies MA, Long GV, Tawbi HA, Goldberg SB, Chiang VL. Reply to A. Shinde et al. J Clin Oncol 37(12):JCO1802463, 2019. e-Pub 2019. PMID: 30807233.
5. Ferguson SD, Zheng S, Xiu J, Zhou S, Khasraw M, Brastianos PK, Kesari S, Hu J, Rudnick J, Salacz ME, Piccioni D, Huang S, Davies MA, Glitza IC, Heymach JV, Zhang J, Ibrahim NK, DeGroot JF, McCarty J, O'Brien BJ, Sawaya R, Verhaak RGW, Reddy SK, Priebe W, Gatalica Z, Spetzler D, Heimberger AB. Profiles of Brain Metastases: Prioritization of Therapeutic Targets. Int J Cancer 143(11):3019-3026, 2018. e-Pub 2018. PMID: 29923182.
6. Teh JLF, Cheng PF, Purwin TJ, Nikbakht N, Patel P, Chervoneva I, Ertel A, Fortina PM, Kleiber I, HooKim K, Davies MA, Kwong LN, Levesque MP, Dummer R, Aplin AE. Correction: In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms. Cancer Discov 8(12):1654, 2018. PMID: 30510016.
7. Childress MA, Himmelberg SM, Chen H, Deng W, Davies MA, Lovly CM. ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity Cellular phenotypes, and Biochemical Properties. Mol Cancer Res 16(11):1724-1736, 2018. e-Pub 2018. PMID: 30002191.
8. Kugel CH, Douglass SM, Webster MR, Kaur A, Liu Q, Yin X, Weiss SA, Darvishian F, Al-Rohil RN, Ndoye A, Behera R, Alicea GM, Ecker BL, Fane M, Allegrezza MJ, Svoronos N, Kumar V, Wang DY, Somasundaram R, Hu-Lieskovan S, Ozgun A, Herlyn M, Conejo-Garcia JR, Gabrilovich D, Stone EL, Nowicki TS, Sosman J, Rai R, Carlino MS, Long GV, Marais R, Ribas A, Eroglu Z, Davies MA, Schilling B, Schadendorf D, Xu W, Amaravadi RK, Menzies AM, McQuade JL, Johnson DB, Osman I, Weeraratna AT. Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. Clin Cancer Res 24(21):5347-5356, 2018. e-Pub 2018. PMID: 29898988.
9. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 24(11):1649-1654, 2018. e-Pub 2018. PMID: 30297909.
10. Johnson DH, Zobniw CM, Trinh VA, Ma J, Bassett RL, Abdel-Wahab N, Anderson J, Davis JE, Joseph J, Uemura M, Noman A, Abu-Sbeih H, Yee C, Amaria R, Patel S, Tawbi H, Glitza IC, Davies MA, Wong MK, Woodman S, Hwu WJ, Hwu P, Wang Y, Diab A. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer 6(1):103, 2018. e-Pub 2018. PMID: 30305177.
11. Capparelli C, Purwin TJ, Heilman SA, Chervoneva I, McCue PA, Berger AC, Davies MA, Gershenwald JE, Krepler C, Aplin AE. ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma. Cancer Res 78(19):5680-5693, 2018. e-Pub 2018. PMID: 30115691.
12. Bezrookove V, Nosrati M, Miller JR, De Semir D, Dar AA, Vosoughi E, Vaquero E, Sucker A, Lazar AJ, Gershenwald JE, Davies MA, Schadendorf D, Kashani-Sabet M. Role of Elevated PHIP Copy Number as a Prognostic and Progression Marker for Cutaneous Melanoma. Clin Cancer Res 24(17):4119-4125, 2018. e-Pub 2018. PMID: 29776954.
13. Forget MA, Haymaker C, Hess KR, Meng YJ, Creasy C, Karpinets T, Fulbright OJ, Roszik J, Woodman SE, Kim YU, Sakellariou-Thompson D, Bhatta A, Wahl A, Flores E, Thorsen ST, Tavera RJ, Ramachandran R, Gonzalez AM, Toth CL, Wardell S, Mansaray R, Patel V, Carpio DJ, Vaughn C, Farinas CM, Velasquez PG, Hwu WJ, Patel SP, Davies MA, Diab A, Glitza IC, Tawbi H, Wong MK, Cain S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Wargo JA, Radvanyi LG, Torres-Cabala CA, Beroukhim R, Hwu P, Amaria RN, Bernatchez C. Prospective analysis of adoptive TIL therapy in patients with metastatic melanoma: response, impact of anti-CTLA4, and biomarkers to predict clinical outcome. Clin Cancer Res 24(18):4416-4428, 2018. e-Pub 2018. PMID: 29848573.
14. Vishnoi M, Boral D, Liu H, Sprouse ML, Yin W, Goswami-Sewell D, Tetzlaff MT, Davies MA, Oliva ICG, Marchetti D. Targeting USP7 identifies a metastasis-competent state within bone marrow-resident melanoma CTCs. Cancer Res 78(18):5349-5362, 2018. e-Pub 2018. PMID: 30026332.
15. Tetzlaff MT, Messina JL, Stein JE, Xu X, Amaria RN, Blank CU, van de Wiel BA, Ferguson PM, Rawson RV, Ross MI, Spillane AJ, Gershenwald JE, Saw RPM, van Akkooi ACJ, van Houdt WJ, Mitchell TC, Menzies AM, Long GV, Wargo JA, Davies MA, Prieto VG, Taube JM, Scolyer RA. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Ann Oncol 29(8):1861-1868, 2018. e-Pub 2018. PMID: 29945191.
16. Huang L, Malu S, McKenzie JA, Andrews MC, Talukder AH, Tieu T, Karpinets T, Haymaker C, Forget MA, Williams LJ, Wang Z, Mbofung RM, Wang ZQ, Davis RE, Lo RS, Wargo JA, Davies MA, Bernatchez C, Heffernan T, Amaria RN, Korkut A, Peng W, Roszik J, Lizée G, Woodman SE, Hwu P. The RNA-binding protein MEX3B mediates resistance to cancer immunotherapy by downregulating HLA-A expression. Clin Cancer Res 24(14):3366-3376, 2018. e-Pub 2018. PMID: 29496759.
17. Ballester LY, Glitza Oliva IC, Douse DY, Chen MM, Lan C, Haydu LE, Huse JT, Roy-Chowdhuri S, Luthra R, Wistuba II, Davies MA. Evaluating Circulating Tumor DNA From the Cerebrospinal Fluid of Patients With Melanoma and Leptomeningeal Disease. J Neuropathol Exp Neurol 77(7):628-635, 2018. e-Pub 2018. PMID: 29873738.
18. Ascierto PA, Puzanov I, Agarwala SS, Bifulco C, Botti G, Caracò C, Ciliberto G, Davies MA, Dummer R, Ferrone S, Gajewski TF, Garbe C, Luke JJ, Marincola FM, Masucci G, Mehnert JM, Mozzillo N, Palmieri G, Postow MA, Schoenberger SP, Wang E, Thurin M. Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy). J Transl Med 16(1):207, 2018. e-Pub 2018. PMID: 30031393.
19. Romano G, Chen PL, Song P, McQuade JL, Liang RJ, Liu M, Roh W, Duose DY, Carapeto FCL, Li J, Teh JLF, Aplin AE, Chen M, Zhang J, Lazar AJ, Davies MA, Futreal PA, Amaria RN, Zhang DY, Wargo JA, Kwong LN. A pre-existing rare PIK3CAE545K subpopulation confers clinical resistance to MEK plus CDK4/6 inhibition in NRAS melanoma and is dependent on S6K1 signaling. Cancer Discov 8(5):556-567, 2018. e-Pub 2018. PMID: 29496665.
20. Teh JLF, Cheng PF, Purwin TJ, Nikbakht N, Patel P, Chervoneva I, Ertel A, Fortina PM, Kleiber I, HooKim K, Davies MA, Kwong LN, Levesque MP, Dummer R, Aplin AE. In vivo E2F reporting reveals efficacious schedules of MEK1/2-CDK4/6 targeting and mTOR-S6 resistance mechanisms. Cancer Discov 8(5):568-581, 2018. e-Pub 2018. PMID: 29496664.
21. McQuade JL, Daniel CR, Davies MA. Body-mass index and metastatic melanoma outcomes - Authors' reply. Lancet Oncol 19(5):e227-e228, 2018. PMID: 29726386.
22. Cascone T, McKenzie JA, Mbofung RM, Punt S, Wang Z, Xu C, Williams LJ, Wang Z, Bristow CA, Carugo A, Peoples MD, Li L, Karpinets T, Huang L, Malu S, Creasy C, Leahey SE, Chen J, Chen Y, Pelicano H, Bernatchez C, Gopal YNV, Heffernan TP, Hu J, Wang J, Amaria RN, Garraway LA, Huang P, Yang P, Wistuba II, Woodman SE, Roszik J, Davis RE, Davies MA, Heymach JV, Hwu P, Peng W. Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. Cell Metab 27(5):977-987.e4, 2018. e-Pub 2018. PMID: 29628419.
23. Fang P, Boehling NS, Koay EJ, Bucheit AD, Jakob JA, Settle SH, Davies MA, Robinson JP, Sulman EP. Melanoma brain metastases harboring BRAF V600K or NRAS mutations are associated with an increased local failure rate following conventional therapy. J Neurooncol 137(1):67-75, 2018. e-Pub 2017. PMID: 29198052.
24. McQuade JL, Daniel CR, Hess KR, Mak C, Wang DY, Rai RR, Park JJ, Haydu LE, Spencer C, Wongchenko M, Lane S, Lee DY, Kaper M, McKean M, Beckermann KE, Rubinstein SM, Rooney I, Musib L, Budha N, Hsu J, Nowicki TS, Avila A, Haas T, Puligandla M, Lee S, Fang S, Wargo JA, Gershenwald JE, Lee JE, Hwu P, Chapman PB, Sosman JA, Schadendorf D, Grob JJ, Flaherty KT, Walker D, Yan Y, McKenna E, Legos JJ, Carlino MS, Ribas A, Kirkwood JM, Long GV, Johnson DB, Menzies AM, Davies MA. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol 19(3):310-322, 2018. e-Pub 2018. PMID: 29449192.
25. Amaria RN*, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, Patel SP, Lee JE, Gershenwald JE, Spencer CN, Gopalakrishnan V, Bassett R, Simpson L, Mouton R, Hudgens CW, Zhao L, Zhu H, Cooper ZA, Wani K, Lazar A, Hwu P, Diab A, Wong MK, McQuade JL, Royal R, Lucci A, Burton EM, Reddy S, Sharma P, Allison J, Futreal PA, Woodman SE, **Davies MA, Wargo JA**. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol 19(2):181-193, 2018. e-Pub 2018. PMID: 29361468 (*and**contributed equally).
26. Bédard PL,Davies MA, Kopetz S, Juric D, Shapiro GI, Luke JJ, Spreafico A, Wu B, Castell C, Gomez C, Cartot-Cotton S, Mazuir F, Dubar M, Micallef S, Demers B, Flaherty KT. First-in-Human Trial of the PI3Kβ-Selective Inhibitor SAR260301 in Patients with Advanced Solid Tumors. Cancer 124(2):315-324, 2018. e-Pub 2017. PMID: 28976556.
27. Yam C, Xu X, Davies MA, Gimotty PA, Morrissette JJ, Tetzlaff MT, Wani K, Liu S, Deng W, Buckley M, Zhao J, Amaravadi RK, Haas N, Kudchadkar RR, Pavlick A, Sosman JA, Tawbi H, Walker L, Schuchter LM, Karakousis GC, Gangadhar TC. A multicenter phase I study evaluating dual PI3K and BRAF inhibition with PX-866 and vemurafenib in patients with advanced BRAF V600 mutant solid tumors. Clin Cancer Res, 2018. e-Pub 2017. PMID: 29051322.
28. Hartsough EJ, Kugel CH, Vido MJ, Berger AC, Purwin TJ, Goldberg A, Davies MA, Schiewer MJ, Knudsen KE, Bollag G, Aplin AE. Response and resistance to paradox breaking BRAF inhibitor in melanomas in vivo and ex vivo. Mol Cancer Ther 17(1):84-95, 2018. e-Pub 2017. PMID: 29133617.
29. Glitza IC, Rohlfs M, Guha-Thakurta N, Bassett RL, Bernatchez C, Diab A, Woodman SE, Yee C, Amaria RN, Patel SP, Tawbi H, Wong M, Hwu WJ, Hwu P, Heimberger A, McCutcheon IE, Papadopoulos N, Davies MA. Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. ESMO Open 3(1):e000283, 2018. e-Pub 2018. PMID: 29387478.
30. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Sloane RS, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Sanchez EMR, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science, 2018. e-Pub 2017. PMID: 29097493.
31. Kwong LN, De Macedo MP, Haydu L, Joon AY, Tetzlaff MT, Calderone TL, Wu CJ, Kwong MK, Roszik J, Hess KR, Davies MA, Lazar AJ, Gershenwald JE. Biological Validation of RNA Sequencing Data From Formalin-Fixed Paraffin-Embedded Primary Melanomas. JCO Precis Oncol 2018, 2018. e-Pub 2018. PMID: 31058252.
32. Robinson JP, Rebecca VW, Kircher DA, Silvis MR, Smalley I, Gibney GT, Lastwika KJ, Chen G, Davies MA, Grossman D, Smalley KSM, Holmen SL, VanBrocklin MW. Resistance mechanisms to genetic suppression of mutant NRAS in melanoma. Melanoma Res 27(6):545-557, 2017. PMID: 29076949.
33. Tetzlaff MT, Jazaeri AA, Torres-Cabala CA, Korivi BR, Landon GA, Nagarajan P, Choksi A, Chen L, Uemura M, Aung PP, Diab A, Sharma P, Davies MA, Amaria R, Prieto VG, Curry JL. Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy. Report of two patients. J Cutan Pathol 44(12):1080-1086, 2017. e-Pub 2017. PMID: 28901560.
34. Ndoye A, Budina-Kolomets A, Kugel CH, Webster MR, Kaur A, Behera R, Rebecca VW, Li L, Brafford PA, Liu Q, Gopal YNV, Davies MA, Mills GB, Xu X, Wu H, Herlyn M, Nicastri MC, Winkler JD, Soengas MS, Amaravadi RK, Murphy ME, Weeraratna AT. ATG5 mediates a positive feedback loop between Wnt signaling and autophagy in melanoma. Cancer Res 77(21):5873-5885, 2017. e-Pub 2017. PMID: 28887323.
35. Krepler C, Sproesser K, Brafford P, Beqiri M, Garman B, Xiao M, Shannan B, Watters A, Perego M, Zhang G, Vultur A, Yin X, Liu Q, Anastopoulos IN, Wubbenhorst B, Wilson MA, Xu W, Karakousis G, Feldman M, Xu X, Amaravadi R, Gangadhar TC, Elder DE, Haydu LE, Wargo JA, Davies MA, Lu Y, Mills GB, Frederick DT, Barzily-Rokni M, Flaherty KT, Hoon DS, Guarino M, Bennett JJ, Ryan RW, Petrelli NJ, Shields CL, Terai M, Sato T, Aplin AE, Roesch A, Darr D, Angus S, Kumar R, Halilovic E, Caponigro G, Jeay S, Wuerthner J, Walter A, Ocker M, Boxer MB, Schuchter L, Nathanson KL, Herlyn M. A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. Cell Rep 21(7):1953-1967, 2017. PMID: 29141225.
36. Garman B, Anastopoulos IN, Krepler C, Brafford P, Sproesser K, Jiang Y, Wubbenhorst B, Amaravadi R, Bennett J, Beqiri M, Elder D, Flaherty KT, Frederick DT, Gangadhar TC, Guarino M, Hoon D, Karakousis G, Liu Q, Mitra N, Petrelli NJ, Schuchter L, Shannan B, Shields CL, Wargo J, Wenz B, Wilson MA, Xiao M, Xu W, Xu X, Yin X, Zhang NR, Davies MA, Herlyn M, Nathanson KL. Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines. Cell Rep 21(7):1936-1952, 2017. PMID: 29141224.
37. Fontanals-Cirera B, Hasson D, Vardabasso C, Di Micco R, Agrawal P, Chowdhury A, Gantz M, de Pablos-Aragoneses A, Morgenstern A, Wu P, Filipescu D, Valle-Garcia D, Darvishian F, Roe JS, Davies MA, Vakoc CR, Hernando E, Bernstein E. Harnessing BET Inhibitor Sensitivity Reveals AMIGO2 as a Melanoma Survival Gene. Mol Cell 68(4):731-744.e9, 2017. e-Pub 2017. PMID: 29149598.
38. An Y, Jiang W, Kim BYS, Qian JM, Tang C, Fang P, Logan J, D'Souza NM, Haydu LE, Wang XA, Hess KR, Kluger H, Glitza IC, Mahajan A, Welsh JW, Lin SH, Yu JB, Davies MA, Hwu P, Sulman EP, Brown PD, Chiang VLS, Li J. Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. Radiother Oncol 125(1):80-88, 2017. e-Pub 2017. PMID: 28916225.
39. Schadendorf D, Long GV, Stroiakovski D, Karaszewska B, Hauschild A, Levchenko E, Chiarion-Sileni V, Schachter J, Garbe C, Dutriaux C, Gogas H, Mandalà M, Haanen JBAG, Lebbé C, Mackiewicz A, Rutkowski P, Grob JJ, Nathan P, Ribas A, Davies MA, Zhang Y, Kaper M, Mookerjee B, Legos JJ, Flaherty KT, Robert C. Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. Eur J Cancer 82:45-55, 2017. e-Pub 2017. PMID: 28648698.
40. Somasundaram R, Zhang G, Fukunaga-Kalabis M, Perego M, Krepler C, Xu X, Wagner C, Hristova D, Zhang J, Tian T, Wei Z, Liu Q, Garg K, Griss J, Hards R, Maurer M, Hafner C, Mayerhöfer M, Karanikas G, Jalili A, Bauer-Pohl V, Weihsengruber F, Rappersberger K, Koller J, Lang R, Hudgens C, Chen G, Tetzlaff M, Wu L, Frederick DT, Scolyer RA, Long GV, Damle M, Ellingsworth C, Grinman L, Choi H, Gavin BJ, Dunagin M, Raj A, Scholler N, Gross L, Beqiri M, Bennett K, Watson I, Schaider H, Davies MA, Wargo J, Czerniecki BJ, Schuchter L, Herlyn D, Flaherty K, Herlyn M, Wagner SN. Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. Nat Commun 8(1):607, 2017. e-Pub 2017. PMID: 28928360.
41. Iida Y, Ciechanover A, Marzese DM, Hata K, Bustos M, Ono S, Wang J, Salomon MP, Tran K, Lam S, Hsu S, Nelson N, Kravtsova-Ivantsiv Y, Mills GB, Davies MA, Hoon DSB. Epigenetic Regulation of KPC1 Ubiquitin Ligase Effects the NF-κB Pathway in Melanoma. Clin Cancer Res 23(16):4831-4842, 2017. e-Pub 2017. PMID: 28389511.
42. Fang S, Wang Y, Dang Y, Gagel A, Ross MI, Gershenwald JE, Cormier JN, Wargo J, Haydu LE, Davies MA, McQuade JL, Sui D, Bassett RL, Reveille JD, Wei Q, Amos CI, Lee JE. Association between body mass index, C-reactive protein levels, and melanoma patient outcomes. J Invest Dermatol 137(8):1792-1795, 2017. e-Pub 2017. PMID: 28442307.
43. Eskiocak B, McMillan EA, Mendiratta S, Kollipara RK, Zhang H, Humphries CG, Wang C, Garcia-Rodriguez J, Ding M, Zaman A, Rosales TI, Eskiocak U, Smith MP, Sudderth J, Komurov K, Deberardinis RJ, Wellbrock C, Davies MA, Wargo JA, Yu Y, De Brabander JK, Williams NS, Chin L, Rizos H, Long GV, Kittler R, White MA. Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma. Cancer Discov 7(8):832-851, 2017. e-Pub 2017. PMID: 28455392.
44. Reuben A*, Petaccia de Macedo M*, McQuade J, Joon A, Ren Z, Calderone T, Conner B, Wani K, Cooper ZA, Tawbi H, Tetzlaff MT, Padera RF, Durand JB, Lazar AJ**, Wargo JA**, **Davies MA. Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab. Oncoimmunology 6(12):e1361097, 2017. e-Pub 2017. PMID: 29209563 (*and**contributed equally).
45. Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JBAG, Hansson J, Utikal J, Ferraresi V, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, Davies MA, Lane SR, Legos JJ, Mookerjee B, Grob JJ. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol 28(7):1631-1639, 2017. e-Pub 2017. PMID: 28475671.
46. Davies MA, Saiag P, Robert C, Grob JJ, Flaherty KT, Arance A, Chiarion-Sileni V, Thomas L, Lesimple T, Mortier L, Moschos SJ, Hogg D, Márquez-Rodas I, Del Vecchio M, Lebbé C, Meyer N, Zhang Y, Huang Y, Mookerjee B, Long GV. Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol 18(7):863-873, 2017. e-Pub 2017. PMID: 28592387.
47. Nagarajan P, Curry JL, Ning J, Piao J, Torres-Cabala CA, Aung PP, Ivan D, Ross MI, Levenback CF, Frumovitz M, Gershenwald JE, Davies MA, Malpica A, Prieto VG, Tetzlaff MT. Tumor thickness and mitotic rate robustly predict melanoma-specific survival in patients with primary vulvar melanoma: A retrospective review of 100 cases. Clin Cancer Res 23(8):2093-2104, 2017. e-Pub 2016. PMID: 27864417.
48. Kim DW, Haydu LE, Joon AY, Bassett RL, Siroy AE, Tetzlaff MT, Routbort MJ, Amaria RN, Wargo JA, McQuade JL, Kemnade J, Hwu P, Woodman SE, Roszik J, Kim KB, Gershenwald JE, Lazar AJ, Davies MA. Clinicopathological features and clinical outcomes associated with TP53 and BRAF (Non-V600) mutations in cutaneous melanoma patients. Cancer 123(8):1372-1381, 2017. e-Pub 2016. PMID: 27911979.
49. Fiziev P, Akdemir KC, Miller JP, Keung EZ, Samant NS, Sharma S, Natale CA, Terranova CJ, Maitituoheti M, Amin SB, Martinez-Ledesma E, Dhamdhere M, Axelrad JB, Shah A, Cheng CS, Mahadeshwar H, Seth S, Barton MC, Protopopov A, Tsai KY, Davies MA, Garcia BA, Amit I, Chin L, Ernst J, Rai K. Systematic Epigenomic Analysis Reveals Chromatin States Associated with Melanoma Progression. Cell Rep 19(4):875-889, 2017. PMID: 28445736.
50. Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy SM, Gumbs C, Little L, Chang Q, Chen WS, Wani K, De Macedo MP, Chen E, Austin-Breneman JL, Jiang H, Roszik J, Tetzlaff MT, Davies MA, Gershenwald JE, Tawbi H, Lazar AJ, Hwu P, Hwu WJ, Diab A, Glitza IC, Patel SP, Woodman SE, Amaria RN, Prieto VG, Hu J, Sharma P, Allison JP, Chin L, Zhang J, Wargo JA, Futreal PA. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med 9(379), 2017. PMID: 28251903.
51. Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, McQuade JL, Shoushtari AN, Tsai KK, Eroglu Z, Klein O, Hassel JC, Sosman JA, Guminski A, Sullivan RJ, Ribas A, Carlino MS, Davies MA, Sandhu SK, Long GV. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 28(2):368-376, 2017. e-Pub 2016. PMID: 27687304.
52. Li J, Zhao W, Akbani R, Liu W, Ju Z, Ling S, Vellano CP, Roebuck P, Yu Q, Eterovic AK, Byers LA, Davies MA, Deng W, Gopal YN, Chen G, von Euw EM, Slamon D, Conklin D, Heymach JV, Gazdar AF, Minna JD, Myers JN, Lu Y, Mills GB, Liang H. Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. Cancer Cell 31(2):225-239, 2017. e-Pub 2016. PMID: 28196595.
53. Shiuan E, Beckermann KE, Ozgun A, Kelly C, McKean M, McQuade J, Thompson MA, Puzanov I, Greer JP, Rapisuwon S, Postow M, Davies MA, Eroglu Z, Johnson D. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. J Immunother Cancer 5:8, 2017. e-Pub 2017. PMID: 28239462.
54. McQuade JL, Posada LP, Lecagoonporn S, Cain S, Bassett RL, Patel SP, Hwu WJ, Hwu P, Davies MA, Bedikian AY, Amaria RN. A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma. Melanoma Res 26(6):604-608, 2016. PMID: 27540836.
55. Long GV, Grob JJ, Nathan P, Ribas A, Robert C, Schadendorf D, Lane SR, Mak C, Legenne P, Flaherty KT, Davies MA. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncol 17(12):1621-1754, 2016. e-Pub 2016. PMID: 27864013.
56. Cohen JV, Tawbi H, Margolin KA, Amravadi R, Bosenberg M, Brastianos PK, Chiang VL, de Groot J, Glitza IC, Herlyn M, Holmen SL, Jilaveanu LB, Lassman A, Moschos S, Postow MA, Thomas R, Tsiouris JA, Wen P, White RM, Turnham T, *Davies MA, Kluger HM*. Melanoma Central Nervous System Metastases: Current Approaches, Challenges, and Opportunities. Pigment Cell Melanoma Res 29(6):627-642, 2016. e-Pub 2016. PMID: 27615400 (*contributed equally).
57. Krepler C, Xiao M, Samanta M, Vultur A, Chen HY, Brafford P, Reyes-Uribe PI, Halloran M, Chen T, He X, Hristova D, Liu Q, Samatar AA, Davies MA, Nathanson KL, Fukunaga-Kalabis M, Herlyn M, Villanueva J. Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma. Oncotarget 7(44):71211-71222, 2016. e-Pub 2016. PMID: 27655717.
58. Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Dummer R, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Garbe C, Huber V, Khleif S, Krauthammer M, Lo RS, Masucci G, Palmieri G, Postow M, Puzanov I, Silk A, Spranger S, Stroncek DF, Tarhini A, Taube JM, Testori A, Wang E, Wargo JA, Yee C, Zarour H, Zitvogel L, Fox BA, Mozzillo N, Marincola FM, Thurin M. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015. J Transl Med 14(1):313, 2016. e-Pub 2016. PMID: 27846884.
59. Roszik J, Haydu LE, Hess KR, Oba J, Joon AY, Siroy AE, Karpinets TV, Stingo FC, Baladandayuthapani V, Tetzlaff MT, Wargo JA, Chen K, Forget MA, Haymaker CL, Chen JQ, Meric-Bernstam F, Eterovic AK, Shaw KR, Mills GB, Gershenwald JE, Radvanyi LG, Hwu P, Futreal PA, Gibbons DL, Lazar AJ, Bernatchez C, Davies MA, Woodman SE. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Med 14(1):168, 2016. e-Pub 2016. PMID: 27776519.
60. Tetzlaff MT, Singh RR, Seviour EG, Curry JL, Hudgens CW, Bell D, Wimmer DA, Ning J, Czerniak BA, Zhang L, Davies MA, Prieto VG, Broaddus RR, Ram P, Luthra R, Esmaeli B. Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma. J Pathol 240(1):84-95, 2016. e-Pub 2016. PMID: 27287813.
61. Teh JL, Purwin TJ, Greenawalt EJ, Chervoneva I, Goldberg A, Davies MA, Aplin AE. An in vivo reporter to quantitatively and temporally analyze the effects of CDK4/6 inhibitor-based therapies in melanoma. Cancer Res 76(18):5455-66, 2016. e-Pub 2016. PMID: 27488531.
62. Chen G, McQuade JL, Panka DJ, Hudgens CW, Amin-Mansour A, Mu XJ, Bahl S, Jané-Valbuena J, Wani KM, Reuben A, Creasy CA, Jiang H, Cooper ZA, Roszik J, Bassett RL, Joon AY, Simpson LM, Mouton RD, Glitza IC, Patel SP, Hwu WJ, Amaria RN, Diab A, Hwu P, Lazar AJ, Wargo JA, Garraway LA, Tetzlaff MT, Sullivan RJ, Kim KB, Davies MA. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. JAMA Oncol 2(8):1056-64, 2016. e-Pub 2016. PMID: 27124486.
63. Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JA. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov 6(8):827-37, 2016. e-Pub 2016. PMID: 27301722.
64. Merlino G, Herlyn M, Fisher DE, Bastian BC, Flaherty KT, Davies MA, Wargo JA, Curiel-Lewandrowski C, Weber MJ, Leachman SA, Soengas MS, McMahon M, Harbour JW, Swetter SM, Aplin AE, Atkins MB, Bosenberg MW, Dummer R, Gershenwald JE, Halpern AC, Herlyn D, Karakousis GC, Kirkwood JM, Krauthammer M, Lo RS, Long GV, McArthur G, Ribas A, Schuchter L, Sosman JA, Smalley KS, Steeg P, Thomas NE, Tsao H, Tueting T, Weeraratna A, Xu G, Lomax R, Martin A, Silverstein S, Turnham T, Ronai ZA. The State of Melanoma: Challenges and Opportunities. Pigment Cell Melanoma Res 29(4):404-16, 2016. e-Pub 2016. PMID: 27087480.
65. Ekmekcioglu S, Davies MA, Tanese K, Roszik J, Shin-Sim M, Bassett RL, Milton DR, Woodman SE, Prieto VG, Gershenwald JE, Morton DL, Hoon DS, Grimm EA. Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and its Expression Associates with Favorable Survival for Stage III Melanoma. Clin Cancer Res 22(12):3016-24, 2016. e-Pub 2016. PMID: 26783288.
66. Goedert L, Pereira CG, Roszik J, Plaça JR, Cardoso C, Chen G, Deng W, Yennu-Nanda VG, Silva WA, Davies MA, Espreafico EM. RMEL3, a novel BRAFV600E-associated long noncoding RNA, is required for MAPK and PI3K signaling in melanoma. Oncotarget 7(24):36711-36718, 2016. e-Pub 2016. PMID: 27167340.
67. Meric-Bernstam F, Brusco L, Daniels M, Wathoo C, Bailey AM, Strong L, Shaw K, Lu K, Qi Y, Zhao H, Lara-Guerra H, Litton J, Arun B, Eterovic AK, Aytac U, Routbort M, Subbiah V, Janku F, Davies MA, Kopetz S, Mendelsohn J, Mills GB, Chen K. Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. Ann Oncol 27(5):795-800, 2016. e-Pub 2016. PMID: 26787237.
68. Zhang G, Frederick DT, Wu L, Wei Z, Krepler C, Srinivasan S, Chae YC, Xu X, Choi H, Dimwamwa E, Ope O, Shannan B, Basu D, Zhang D, Guha M, Xiao M, Randell S, Sproesser K, Xu W, Liu J, Karakousis GC, Schuchter LM, Gangadhar TC, Amaravadi RK, Gu M, Xu C, Ghosh A, Xu W, Tian T, Zhang J, Zha S, Liu Q, Brafford P, Weeraratna A, Davies MA, Wargo JA, Avadhani NG, Lu Y, Mills GB, Altieri DC, Flaherty KT, Herlyn M. Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. J Clin Invest 126(5):1834-56, 2016. e-Pub 2016. PMID: 27043285.
69. Sholl LM, Andea A, Bridge JA, Cheng L, Davies MA, Ehteshami M, Gangadhar TC, Kamel-Reid S, Lazar A, Raparia K, Siroy A, Watson KL, Members of Cancer Biomarker Reporting Committee, College of American Pathologists. Template for Reporting Results of Biomarker Testing of Specimens From Patients With Melanoma. Arch Pathol Lab Med 140(4):355-7, 2016. e-Pub 2015. PMID: 26340412.
70. Tsai WB, Long Y, Park JR, Chang JT, Liu H, Rodriguez-Canales J, Savaraj N, Feun LG, Davies MA, Wistuba II, Kuo MT. Gas6/Axl is the sensor of arginine-auxotrophic response in targeted chemotherapy with arginine-depleting agents. Oncogene 35(13):1632-42, 2016. e-Pub 2015. PMID: 26096933.
71. Cooper ZA, Reuben A, Spencer CN, Prieto PA, Austin-Breneman JL, Jiang H, Haymaker C, Gopalakrishnan V, Tetzlaff MT, Frederick DT, Sullivan RJ, Amaria RN, Patel SP, Hwu P, Woodman SE, Glitza IC, Diab A, Vence LM, Rodriguez-Canales J, Parra ER, Wistuba II, Coussens LM, Sharpe AH, Flaherty KT, Gershenwald JE, Chin L, Davies MA, Clise-Dwyer K, Allison JP, Sharma P, Wargo JA. Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Oncoimmunology 5(3):e1136044, 2016. e-Pub 2016. PMID: 27141370.
72. Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, Torres-Cabala CA, Cooper ZA, Chen PL, Tieu TN, Spranger S, Yu X, Bernatchez C, Forget MA, Haymaker C, Amaria R, McQuade JL, Glitza IC, Cascone T, Li HS, Kwong LN, Heffernan TP, Hu J, Bassett RL, Bosenberg MW, Woodman SE, Overwijk WW, Lizée G, Roszik J, Gajewski TF, Wargo JA, Gershenwald JE, Radvanyi L, *Davies MA, *Hwu P. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov 6(2):202-16, 2016. e-Pub 2015. PMID: 26645196 (*contributed equally).
73. Vu HL, Rosenbaum S, Capparelli C, Purwin TJ, Davies MA, Berger AC, Aplin AE. MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRAS Melanoma. J Invest Dermatol 136(2):453-63, 2016. e-Pub 2015. PMID: 26967478.
74. Roszik J, Wu CJ, Siroy AE, Lazar AJ, Davies MA, Woodman SE, Kwong LN. Somatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene Expression. Sci Rep 6:19649, 2016. e-Pub 2016. PMID: 26787600.
75. Zand B, Previs RA, Zacharias NM, Rupaimoole R, Mitamura T, Nagaraja AS, Guindani M, Dalton HJ, Yang L, Baddour J, Achreja A, Hu W, Pecot CV, Ivan C, Wu SY, McCullough CR, Gharpure KM, Shoshan E, Pradeep S, Mangala LS, Rodriguez-Aguayo C, Wang Y, Nick AM, Davies MA, Armaiz-Pena G, Liu J, Lutgendorf SK, Baggerly KA, Eli MB, Lopez-Berestein G, Nagrath D, Bhattacharya PK, Sood AK. Role of Increased n-acetylaspartate Levels in Cancer. J Natl Cancer Inst 108(6):djv426, 2016. e-Pub 2016. PMID: 26819345.
76. Feng Y, Pinkerton AB, Hulea L, Zhang T, Davies MA, Grotegut S, Cheli Y, Yin H, Lau E, Kim H, De SK, Barile E, Pellecchia M, Bosenberg M, Li JL, James B, Hassig CA, Brown KM, Topisirovic I, Ronai ZA. SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex. Cancer Res 75(75):5211-5218, 2015. e-Pub 2015. PMID: 26603897.
77. Glitza IC, Haymaker C, Bernatchez C, Vence LM, Rohlfs ML, Richard J, Lacey C, Mansaray R, Fulbright OJ, Ramachandran R, Toth C, Wardell S, Woodman SE, Patel S, Hwu WJ, Radvanyi L,Davies MA, Papadopoulos NE, Hwu P. Intrathecal administration of tumor-infiltrating lymphocytes is well tolerated in a patient with leptomeningeal disease from metastatic melanoma: A case report. Cancer Immunol Res 3(11):1201-6, 2015. e-Pub 2015. PMID: 26216417.
78. Hong D, Kurzrock R, Wheler JJ, Naing A, Falchook GS, Fu S, Kim KB, Davies MA, Nguyen LM, George GC, Xu L, Shumaker R, Ren M, Mink J, Bedell C, Andresen C, Sachdev P, O'Brien JP, Nemunaitis J. Phase I dose-escalation study of the multikinase inhibitor lenvatinib in patients with advanced solid tumors and in an expanded cohort of patients with melanoma. Clin Cancer Res 21(21):4801-10, 2015. e-Pub 2015. PMID: 26169970.
79. Ascierto PA, Atkins M, Bifulco C, Botti G, Cochran A, Davies MA, Demaria S, Dummer R, Ferrone S, Formenti S, Gajewski TF, Garbe C, Khleif S, Kiessling R, Lo R, Lorigan P, Arthur GM, Masucci G, Melero I, Mihm M, Palmieri G, Parmiani G, Puzanov I, Romero P, Schilling B, Seliger B, Stroncek D, Taube J, Tomei S, Zarour HM, Testori A, Wang E, Galon J, Ciliberto G, Mozzillo N, Marincola FM, Thurin M. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014. J Transl Med 13(1):374, 2015. e-Pub 2015. PMID: 26619946.
80. Cho JH, Robinson JP, Arave RA, Burnett WJ, Kircher DA, Chen G, Davies MA, Grossmann AH, VanBrocklin MW, McMahon M, Holmen SL. AKT1 Activation Promotes Development of Melanoma Metastases. Cell Rep 13(5):898-905, 2015. e-Pub 2015. PMID: 26565903.
81. Meric-Bernstam F, Brusco L, Shaw K, Horombe C, Kopetz S, Davies MA, Routbort M, Piha-Paul SA, Janku F, Ueno N, Hong D, De Groot J, Ravi V, Li Y, Luthra R, Patel K, Broaddus R, Mendelsohn J, Mills GB. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. J Clin Oncol 33(25):2753-62, 2015. e-Pub 2015. PMID: 26014291.
82. Vu HL, Rosenbaum S, Purwin TJ, Davies MA, Aplin AE. RAC1 P29S regulates PD-L1 expression in melanoma. Pigment Cell Melanoma Res 28(5):590-8, 2015. e-Pub 2015. PMID: 26176707.
83. Capparelli C, Rosenbaum S, Berman-Booty LD, Salhi A, Gaborit N, Zhan T, Chervoneva I, Roszik J, Woodman SE, Davies MA, Setiady YY, Osman I, Yarden Y, Aplin AE. ErbB3/ErbB2 complexes as a therapeutic target in a subset of wild-type BRAF/NRAS cutaneous melanomas. Cancer Res 75(15):3554-67, 2015. e-Pub 2015. PMID: 26206558.
84. Tetzlaff MT, Pattanaprichakul P, Wargo J, Fox PS, Patel KP, Estrella JS, Broaddus RR, Williams MD, Davies MA, Routbort MJ, Lazar AJ, Woodman SE, Hwu WJ, Gershenwald JE, Prieto VG, Torres-Cabala CA, Curry JL. Utility of BRAF V600E immunohistochemical expression pattern as a surrogate of BRAF mutation status in 154 patients with advanced melanoma. Hum Pathol 46(8):1101-10, 2015. e-Pub 2015. PMID: 26058727.
85. Meric-Bernstam F, Johnson A, Holla V, Bailey AM, Brusco L, Chen K, Routbort M, Patel KP, Zeng J, Kopetz S, Davies MA, Piha-Paul SA, Hong DS, Eterovic AK, Tsimberidou AM, Broaddus R, Bernstam EV, Shaw KR, Mendelsohn J, Mills GB. A decision support framework for genomically informed investigational cancer therapy. J Natl Cancer Inst 107(7), 2015. e-Pub 2015. PMID: 25863335.
86. Goswami RS, Patel KP, Singh RR, Meric-Bernstam F, Kopetz ES, Subbiah V, Alvarez RH, Davies MA, Jabbar KJ, Roy-Chowdhuri S, Lazar AJ, Medeiros LJ, Broaddus RR, Luthra R, Routbort MJ. Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors. Clin Cancer Res 21(11):2644-51, 2015. e-Pub 2015. PMID: 25695693.
87. Bradley SD, Chen Z, Melendez B, Talukder A, Khalili JS, Rodriguez-Cruz T, Liu S, Whittington M, Deng W, Li F, Bernatchez C, Radvanyi LG, Davies MA, Hwu P, Lizée G. BRAF(V600E) co-opts a conserved MHC class I internalization pathway to diminish antigen presentation and CD8+ T-cell recognition of melanoma. Cancer Immunol Res 3(6):602-9, 2015. e-Pub 2015. PMID: 25795007.
88. Cancer Genome Atlas Network. Genomic Classification of Cutaneous Melanoma. Cell 161(7):1681-96, 2015. PMID: 26091043.
89. Stockman DL, Curry JL, Torres-Cabala CA, Watson IR, Siroy AE, Bassett RL, Zou L, Patel KP, Luthra R, Davies MA, Wargo JA, Routbort MA, Broaddus RR, Prieto VG, Lazar AJ, Tetzlaff MT. Use of Clinical Next-Generation Sequencing To Identify Melanomas Harboring SMARCB1 Mutations. J Cutan Pathol 42(5):308-17, 2015. e-Pub 2015. PMID: 25754356.
90. Scortegagna M, Lau E, Zhang T, Feng Y, Sereduk C, Yin H, De SK, Meeth K, Platt JT, Langdon CG, Halaban R, Pellecchia M, Davies MA, Brown K, Stern DF, Bosenberg M, Ronai ZA. PDK1 and SGK3 contribute to the growth of BRAF mutant melanomas and are potential therapeutic targets. Cancer Res 75(7):1399-412, 2015. e-Pub 2015. PMID: 25712345.
91. Ju Z, Liu W, Roebuck PL, Siwak DR, Zhang N, Lu Y, Davies MA, Akbani R, Weinstein JN, Mills GB, Coombes KR. Development of a robust classifier for quality control of reverse-phase protein arrays. Bioinformatics 31(6):912-8, 2015. e-Pub 2014. PMID: 25380958.
92. Chen K, Meric-Bernstam F, Zhao H, Zhang Q, Ezzeddine N, Tang LY, Qi Y, Mao Y, Chen T, Chong Z, Zhou W, Zheng X, Johnson A, Aldape KD, Routbort MJ, Luthra R, Kopetz S, Davies MA, de Groot J, Moulder S, Vinod R, Farhangfar CJ, Shaw KM, Mendelsohn J, Mills GB, Eterovic AK. Clinical actionability enhanced through deep targeted sequencing of solid tumors. Clin Chem 61(3):544-53, 2015. e-Pub 2015. PMID: 25626406.
93. Turley RS, Tokuhisa Y, Toshimitsu H, Lidsky ME, Padussis JC, Fontanella A, Deng W, Augustine CK, Beasley GM, Davies MA, Dewhirst MW, Tyler DS. Targeting N-cadherin Increases Vascular Permeability and Differentially Activates AKT in Melanoma. Ann Surg 261(2):368-77, 2015. e-Pub 2014. PMID: 24646553.
94. Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, Haydu L, Prieto VG, Tetzlaff M, Ivan D, Wang WL, Torres-Cabala C, Curry J, Roy-Chowdhuri S, Broaddus R, Rashid A, Stewart J, Gershenwald JE, Amaria RN, Patel SP, Papadopoulos NE, Bedikian A, Hwu WJ, Hwu P, Diab A, Woodman SE, Aldape KD, Luthra R, Patel KP, Shaw KR, Mills GB, Mendelsohn J, Meric-Bernstam F, Kim KB, Routbort MJ, Lazar AJ, Davies MA. Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol 135(2):508-15, 2015. e-Pub 2014. PMID: 25148578.
95. Damsky W, Micevic G, Meeth K, Muthusamy V, Curley DP, Santhanakrishnan M, Erdelyi I, Platt JT, Huang L, Theodosakis N, Zaidi MR, Tighe S, Davies MA, Dankort D, McMahon M, Merlino G, Bardeesy N, Bosenberg M. mTORC1 activation blocks Braf V600E - induced growth arrest, but is insufficient for melanoma formation. Cancer Cell 27(1):41-56, 2015. PMID: 25584893.
96. Gopal YN, Rizos H, Chen G, Deng W, Frederick DT, Cooper ZA, Scolyer RA, Pupo G, Komurov K, Sehgal V, Zhang J, Patel L, Pereira CG, Broom BM, Mills GB, Ram P, Smith PD, Wargo JA, Long GV, Davies MA. Inhibition of mTORC1/2 overcomes PGC1a and OxPhos-mediated resistance. Cancer Res 74(23):7037-47, 2014. e-Pub 2014. PMID: 25297634.
97. Chen G, Chakravarti N, Aardalen K, Lazar AJ, Tetzlaff MT, Wubbenhorst B, Kim SB, Kopetz S, Ledoux AA, Gopal YN, Pereira CG, Deng W, Lee JS, Nathanson KL, Aldape KD, Prieto VG, Stuart D, Davies MA. Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target. Clin Cancer Res 20(21):5537-46, 2014. e-Pub 2014. PMID: 24803579.
98. Bucheit AD, Chen G, Siroy A, Tetzlaff M, Broaddus R, Milton D, Fox P, Bassett R, Hwu P, Gershenwald JE, Lazar AJ, Davies MA. Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations. Clin Cancer Res 20(21):5527-36, 2014. e-Pub 2014. PMID: 25165098.
99. Watson IR, Li L, Cabeceiras PK, Mahdavi M, Gutschner T, Genovese G, Wang G, Fang Z, Tepper JM, Stemke-Hale K, Tsai KY, Davies MA, Mills GB, Chin L. The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF. Cancer Res 74(17):4845-4852, 2014. e-Pub 2014. PMID: 25056119.
100. Alrwas A, Papadopoulos NE, Cain S, Patel SP, Kim KB, Deburr TL, Bassett R, Hwu WJ, Bedikian AY, Davies MA, Woodman SE, Hwu P. Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic melanoma. Melanoma Res 24(4):342-8, 2014. e-Pub 2014. PMID: 24743052.
101. Kugel CH, Hartsough EJ, Davies MA, Setiady YY, Aplin AE. Function-Blocking ERBB3 Antibody Inhibits the Adaptive Response to RAF Inhibitor. Cancer Res 74(15):4122-32, 2014. e-Pub 2014. PMID: 25035390.
102. Dutton-Regester K, Gartner JJ, Emmanuel R, Qutob N, Davies MA, Gershenwald JE, Robinson W, Robinson S, Rosenberg SA, Scolyer RA, Mann GJ, Thompson JF, Hayward NK, Samuels Y. A highly recurrent RPS27 5'UTR mutation in melanoma. Oncotarget 5(10):2912-7, 2014. PMID: 24913145.
103. Ma XH, Piao SF, Dey S, McAfee Q, Karakousis G, Villanueva J, Hart LS, Levi S, Hu J, Zhang G, Lazova R, Klump V, Pawelek JM, Xu X, Xu W, Schuchter LM, Davies MA, Herlyn M, Winkler J, Koumenis C, Amaravadi RK. Targeting ER stress induced-autophagy overcomes resistance to BRAF inhibition in melanoma. J Clin Invest 124(3):1406-17, 2014. e-Pub 2014. PMID: 24569374.
104. Prickett TD, Zerlanko B, Gartner JJ, Parker SC, Dutton-Regester K, Lin JC, Teer JK, Wei X, Jiang J, NISC Comparative Sequencing Program, Chen G, Davies MA, Gershenwald JE, Robinson W, Robinson S, Hayward NK, Rosenberg SA, Margulies EH, Samuels Y. Somatic Mutations in MAP3K5 Attenuate Its Proapoptotic Function in Melanoma through Increased Binding to Thioredoxin. J Invest Dermatol 134(2):452-60, 2014. e-Pub 2013. PMID: 24008424.
105. Lopez-Rivera E, Jayaraman P, Parikh F, Davies MA, Ekmekcioglu S, Izadmehr S, Milton DR, Chipuk JE, Grimm EA, Estrada Y, Aguirre-Ghiso JA, Sikora AG. Inducible nitric oxide synthase drives mTOR pathway activation and proliferation of human melanoma by reversible nitrosylation of TSC2. Cancer Res 74(4):1067-87, 2014. e-Pub 2014. PMID: 24398473.
106. Curry JL, Davies MA, Calderone TL, Nathanson K, Prieto VG, Gershenwald JE. Tissue resources for clinical use and marker studies in melanoma. Methods Mol Biol 1102:679-95, 2014. PMID: 24259006.
107. Frederick DT, Salas Fragomeni RA, Schalck A, Ferreiro-Neira I, Hoff T, Cooper ZA, Haq R, Panka DJ, Kwong LN, Davies MA, Cusack JC, Flaherty KT, Fisher DE, Mier JW, Wargo JA, Sullivan RJ. Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale. PLoS One 9(7):e101286, 2014. e-Pub 2014. PMID: 24983357.
108. Baladandayuthapani V, Talluri R, Ji Y, Coombes KR, Lu Y, Hennessy BT, Davies MA, Mallick BK. Bayesian sparse graphical models for classification with application to protein expression data. Ann Appl Stat 8(3):1443-1468, 2014. PMID: 26246866.
109. Bucheit AD, Syklawer E, Jakob JA, Bassett RL, Curry JL, Gershenwald JE, Kim KB, Hwu P, Lazar AJ, Davies MA. Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma. Cancer 119(21):3821-9, 2013. e-Pub 2013. PMID: 23922205.
110. Nathanson KL, Martin AM, Wubbenhorst B, Greshock J, Letrero R, D'Andrea K, O'Day S, Infante JR, Falchook GS, Arkenau HT, Millward M, Brown MP, Pavlick A, Davies MA, Ma B, Gagnon R, Curtis CM, Lebowitz PF, Kefford RF, Long GV. Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF ihibitor Dabrafenib (GSK2118436). Clin Cancer Res 19(17):4868-78, 2013. e-Pub 2013. PMID: 23833299.
111. Bowles DW, Ma WW, Senzer N, Brahmer JR, Adjei AA, Davies MA, Lazar AJ, Vo A, Peterson S, Walker L, Hausman D, Rudin CM, Jimeno A. A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours. Br J Cancer 109(5):1085-92, 2013. e-Pub 2013. PMID: 23942080.
112. Gartner JJ, Parker SC, Prickett TD, Dutton-Regester K, Stitzel ML, Lin JC, Davis S, Simhadri VL, Jha S, Katagiri N, Gotea V, Teer JK, Wei X, Morken MA, Bhanot UK, NISC Comparative Sequencing Program, Chen G, Elnitski LL, Davies MA, Gershenwald JE, Carter H, Karchin R, Robinson W, Robinson S, Rosenberg SA, Collins FS, Parmigiani G, Komar AA, Kimchi-Sarfaty C, Hayward NK, Margulies EH, Samuels Y. Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma. Proc Natl Acad Sci U S A 110(33):13481-6, 2013. e-Pub 2013. PMID: 23901115.
113. Overman MJ, Zhang J, Kopetz S, Davies MA, Jiang Z, Stemke-Hale K, Hamilton S, Hwang R, Abbruzzese JL, Varadhachary G, Broom B, Wang H. Gene expression profiling of amupllary carcinomas classifies ampullary carcinomas into biliary-like and intestinal-like subtypes that are prognostic of outcome. PLOS One 8(6), 2013. PMID: 23776447.
114. Greaves WO, Verma S, Patel KP, Davies MA, Barkoh BA, Galbincea JM, Yao H, Lazar AJ, Aldape KD, Medeiros LJ, Luthra R. Frequency and Spectrum of BRAF Mutations in a Retrospective, Single-Institution Study of 1112 Cases of Melanoma. J Mol Diagn 15(2):220-6, 2013. e-Pub 2012. PMID: 23273605.
115. Patel SP, Lazar AJ, Papadopoulos NE, Liu P, Infante JR, Glass MR, Vaughn CS, Lorusso PM, Cohen RB, Davies MA, Kim KB. Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma. Cancer 119(4):799-805, 2013. e-Pub 2012. PMID: 22972589.
116. Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R, Dayyani F, Gopal YN, Jiang ZQ, Wistuba II, Tang XM, Bornman WG, Bollag G, Mills GB, Powis G, Desai J, Gallick GE, Davies MA, Kopetz S. Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents. Clin Cancer Res 19(3):657-667, 2013. e-Pub 2012. PMID: 23251002.
117. Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo JA, Chen JQ, Li HS, Watowich SS, Yang Y, Frederick DT, Cooper ZA, Mbofung RM, Whittington M, Flaherty KT, Woodman SE, Davies MA, Radvanyi LG, Overwijk WW, Lizée G, Hwu P. BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Anti-tumor Activity of Adoptive Immunotherapy in Mice. Clin Cancer Res 19(2):393-403, 2013. e-Pub 2012. PMID: 23204132.
118. Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, Wu R, Lizee G, Mahoney S, Alvarado G, Glass M, Johnson VE, McMannis JD, Shpall E, Prieto V, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Patel S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Davies MA, Mansaray R, Fulbright OJ, Toth C, Ramachandran R, Wardell S, Gonzalez A, Hwu P. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res 18(24):6758-70, 2012. e-Pub 2012. PMID: 23032743.
119. Beasley GM, Coleman AP, Raymond A, Sanders G, Selim MA, Peterson BL, Brady MS, Davies MA, Augustine C, Tyler DS. A phase I multi-institutional sudy of systemic sorafenib in conjunction wiht regional melphalan for in-transit melanoma of the extremity. Ann Surg Oncol 19(12):3896-905, 2012. e-Pub 2012. PMID: 22549288.
120. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, Puzanov I, Hauschild A, Robert C, Algazi A, Mortier L, Tawbi H, Wilhelm T, Zimmer L, Switzky J, Swann S, Martin AM, Guckert M, Goodman V, Streit M, Kirkwood JM, Schadendorf D. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13(11):1087-95, 2012. e-Pub 2012. PMID: 23051966.
121. Joseph RW, Eckel-Passow JE, Sharma R, Liu P, Parker A, Jakob J, Buchbinder E, Bassett RL, Davies MA, Hwu P, Atkins MB, Sullivan RJ. Characterizing the Clinical Benefit of Ipilimumab in Patients Who Progressed on High-dose IL-2. J Immunother 35(9):711-715, 2012. PMID: 23090080.
122. Khalili JS, Liu S, Rodríguez-Cruz TG, Whittington M, Wardell S, Liu C, Zhang M, Cooper ZA, Frederick DT, Li Y, Zhang M, Joseph RW, Bernatchez C, Ekmekcioglu S, Grimm E, Radvanyi LG, Davis RE, Davies MA, Wargo JA, Hwu P, Lizée G. Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma. Clin Cancer Res 18(19):5329-40, 2012. e-Pub 2012. PMID: 22850568.
123. Kim J, Lazar AJ, Davies MA, Homsi J, Papadopoulos NE, Hwu WJ, Bedikian AY, Woodman SE, Patel SP, Hwu P, Kim KB. BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma. J Cutan Pathol 39(9):821-5, 2012. e-Pub 2012. PMID: 22809251.
124. Jakob JA, Bassett RL, Ng CS, Curry JL, Joseph RW, Alvarado GC, Rohlfs ML, Richard J, Gershenwald JE, Hwu P, Kim KB, Lazar AJ, Davies MA. NRAS mutation status is an independent prognostic factor in Metastatic Melanoma. Cancer - Am Cancer Soc 118(16):4014-23, 2012. e-Pub 2011. PMID: 22180178.
125. Khalili JS, Yu X, Wang J, Hayes BC, Davies MA, Lizee G, Esmaeli B, Woodman SE. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ and GNA11 dependant manner. Clin Cancer Res 18(16):4345-55, 2012. e-Pub 2012. PMID: 22733540.
126. Alvarado G, Noor R, Basset R, Papadopoulos NE Kim KB, Hwu WJ, Bedikian A, Patel S, Hwu P, Davies MA. Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with brain metastases. Melanoma Res 22(4):310-5, 2012. PMID: 22584956.
127. Chattopadhyay C, Ellerhorst JA, Ekmekcioglu S, Greene VR, Davies MA, Grimm EA. Association of activated c-Met with NRAS-mutated human melanomas: A possible avenue for targeting. Int J Cancer 131(2):E56-65, 2012. e-Pub 2012. PMID: 22020736.
128. Hatiboglu MA, Kong LY, Wei J, Wang Y, McEnery KA, Fuller GN, Qiao W, Davies MA, Priebe W, Heimberger AB. The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models. Int J Cancer 131(1):8-17, 2012. e-Pub 2011. PMID: 21792892.
129. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C, Dicara D, Ramos AH, Lawrence MS, Cibulskis K, Sivachenko A, Voet D, Saksena G, Stransky N, Onofrio RC, Winckler W, Ardlie K, Wagle N, Wargo J, Chong K, Morton DL, Stemke-Hale K, Chen G, Noble M, Meyerson M, Ladbury JE, Davies MA, Gershenwald JE, Wagner SN, Hoon DS, Schadendorf D, Lander ES, Gabriel SB, Getz G, Garraway LA, Chin L. A Landscape of Driver Mutations in Melanoma. Cell 150(2):251-263, 2012. PMID: 22817889.
130. Al-Zaid T, Ditelberg JS, Prieto VG, Lev D, Luthra R, Davies MA, Diwan AH, Wang WL, Lazar AJ. Trichilemmomas show loss of PTEN in Cowden Syndrome but only rarely in sporadic tumors. J Cutan Pathol 39(5):493-9, 2012. e-Pub 2012. PMID: 22486434.
131. Mu H, Calderone TL, Davies MA, Prieto VG, Wang H, Mills GB, Bar-Eli M, Gershenwald JE. Lysophosphatidic Acid induces lymphangiogenesis and IL-8 production in vitro in human lymphatic endothelial cells. Am J Pathol 180(5):2170-81, 2012. e-Pub 2012. PMID: 22465753.
132. Deng W, Yennu-Nanda VG, Woodman SE, Davies MA. Role and therapeutic potential of PI3K-mTor in de novo resistance to BRAF inhibition. Pigm Cell Melanoma Res 25(2):248-58, 2012. e-Pub 2012. PMID: 22171948.
133. Davies MA, Fox PS, Papadopoulos NE, Bedikian AY, Hwu WJ, Lazar AJ, Prieto VG, Culotta KS, Madden TL, Xu Q, Huang S, Deng W, Ng C, Gupta S, Liu W, Dancey JE, Wright JJ, Bassett RL, Hwu P, Kim KB. Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. Clin Cancer Res 18(4):1120-8, 2012. e-Pub 2012. PMID: 22223528.
134. Joseph RW, Sullivan RJ, Harrell R, Stemke-Hale K, Panka D, Manoukian G, Percy A, Bassett RL, Ng CS, Radvanyi L, Hwu P, Atkins MB, Davies MA. Correlation of NRAS mutations with clinical response to high dose IL-2 in patients with advanced melanoma. J Immunother 35(1):66-72, 2012. PMID: 22130161.
135. Bedikian AY, Wei C, Detry M, Kim KB, Papadopoulos NE, Hwu WJ, Homsi J,Davies MA, McIntyre S, Hwu P. Predictive Factors for the Development of Brain Metastasis in Advanced Unresectable Metastatic Melanoma. Am J Clin Oncol 34(6):603-10, 2011. e-Pub 2010. PMID: 21150567.
136. Prickett TD, Wei X, Teer J, Cherukuri PF, Lin, JC, Molinolo A, Rosenberg SA, Davies MA, Gershenwald JE, Stemke-Hale K, Margulies EH, Samuels Y. Exon Capture Analysis of G-Protein Coupled Receptors Reveals Activating Mutatinos in GRM3 in Melanoma. Nat Genet 43(11):1119-26, 2011. e-Pub 2011. PMID: 21946352.
137. Bedikian AY, Silverman JA, Papodopolous NE, Kim KB, Hagey AE, Vardeleon A, Hwu WJ, Homsi J, Davies MA, Hwu P. Pharmacokinetics and Safety of Marqibo (Vincristine Sulfate Liposomes Injection) in Cancer Patients with Impaired Liver Function. J Clin Pharmacol 51(8):1205-12, 2011. e-Pub 2010. PMID: 20978276.
138. Wei X, Walia V, Lin JC, Teer JK, Prickett TD, Gartner J, Davis S, NISC Comparative Sequencing Program, Stemke-Hale K, Davies MA, Gershenwald JE, Robinson W, Robinson S, Rosenberg SA, Samuels Y. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet 43(5):442-6, 2011. e-Pub 2011. PMID: 21499247.
139. Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ, Hwu P, Bedikian A. Prognostic Factors for Survival in Melanoma Patients with Brain Metastases. Cancer - Am Cancer Soc 117(8):1687-96, 2011. e-Pub 2010. PMID: 20960525.
140. Jilaveanu LB, Zito CR, Aziz SA, Chakraborty A, Davies MA, Camp RL, Rimm DL, Dudek A, Sznol M, Kluger HM. In vitro studies of dasatinib, its targets and predictors of sensitivity. Pigment Cell Melanoma Res 2(24):386-9, 2011. e-Pub 2011. PMID: 21320292.
141. Hennessy BT, Gonzalez-Angulo AM, Carey MS, Myhre S, Ju Z, Davies MA, Liu W, Coombes K, Meric-Bernstam F, Bedrosian I, McGahren M, Agarwal R, Zhang F, Overgaard J, Alsner J, Neve RM, Kuo WL, Gray JW, Borresen Dale AL, Mills GB. A technical assessment of the utility of reverse phase protein arrays for the study of the functional proteome in non-microdissected human breast cancers. Clin Proteomics 6(4):129-151, 2010. PMID: 21691416.
142. Gopal YN, Deng W, Woodman SE, Komurov K, Ram P, Smith PD, Davies MA. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res 70(21):8736-8747, 2010. e-Pub 2010. PMID: 20959481.
143. Wei X, Prickett TD, Viloria CG, Molinolo A, Lin JC, Cardenas-Navia I, Cruz P, NISC Comparative Sequencing Program, Rosenberg SA,Davies MA, Gershenwald JE, López-Otín C, Samuels Y. Mutational and functional analysis reveals ADAMTS18 metalloproteinase as a novel driver in melanoma. Mol Cancer Res 8(11):1513-25, 2010. e-Pub 2010. PMID: 21047771.
144. Altman MK, Gopal V, Jia W, Yu S, Hall H, Mills GB, McGinnis AC, Bartlett MG, Jiang G, Madan D, Prestwich GD, Xu Y, Davies MA, Murph MM. Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid. Mol Cancer 9:140, 2010. PMID: 20529378.
145. Ding Z, Liang J, Li J, Lu Y, Ariyaratna V, Lu Z, Davies MA, Westwick JK, Mills GB. Physical Association of PDK1 with AKT1 is Sufficient for Pathway Activation Independent of Membrane Localization and Phosphatidylinositol 3 Kinase. PLoS One 5(3):e9910, 2010. PMID: 20361045.
146. Sikora AG, Gelbard A, Davies MA, Sano D, Ekmekcioglu S, Kwon J, Hailemichael Y, Jayaraman P, Myers JN, Grimm EA, Overwijk WW. Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy. Clin Cancer Res 16(6):1834-44, 2010. e-Pub 2010. PMID: 20215556.
147. Park ES, Rabinovsky R, Carey M, Hennessy BT, Agarwal R, Liu W, Ju Z, Deng W, Lu Y, Woo HG, Kim SB, Cheong JH, Garraway LA, Weinstein JN, Mills GB, Lee JS, Davies MA. Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. Mol Cancer Ther 9(2):257-67, 2010. e-Pub 2010. PMID: 20124458.
148. Davies MA, Stemke-Hale K, Lin E, Tellez C, Deng W, Gopal YN, Woodman SE, Calderone TC, Ju Z, Lazar AJ, Prieto VG, Aldape K, Mills GB, Gershenwald JE. Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clin Cancer Res 15(24):7538-7546, 2009. PMID: 19996208.
149. Torres-Cabala CA, Wang WL, Trent J, Yang D, Chen S, Galbincea J, Kim KB, Woodman S, Davies MA, Plaza JA, Nash JW, Prieto VG, Lazar AJ, Ivan D. Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod Pathol 22(11):1446-56, 2009. e-Pub 2009. PMID: 19718013.
150. Woodman SE, Trent JC, Stemke-Hale K, Lazar AJ, Pricl S, Pavan GM, Fermeglia M, Vashisht Gopal YN, Yang D, Podoloff DA, Ivan D, Kim KB, Papadopoulos N, Hwu P, Mills GB, Davies MA. Activity of Dasatinib Against L576P KIT Mutant Melanoma: Molecular, Cellular, and Clinical Correlates. Mol Cancer Ther 8(8):2079-85, 2009. e-Pub 2009. PMID: 19671763.
151. Vasudevan KM*, Barbie DA*, Davies MA*, Rabinovsky R, Hennessy BT, Tseng H, Pochanard P, Kim SY, Dunn IF, Schinzel AC, McNear CJ, Sandy P, Hoesch S, Sheng Q, Gupta P, Boehm JS, Reiling JH, Silver S, Lu Y, Stemke-Hale K, Dutta B, Joy C, Sahin AA, Gonzalez-Angulo AM, Lluch A, Rameh LE, Jacks T, Root DE, Lander ES, Mills GB, Hahn WC, Sellers WR, Garraway LA. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer *Featured on Cover. Cancer Cell 16(1):21-32, 2009. PMID: 19573809 (*contributed equally).
152. Aziz SA, Davies MA, Pick E, Zito C, Jilaveanu L, Camp RL, Rimm DL, Kluger Y, Kluger HM. Phosphatidylinositol-3-kinase as a therapeutic target in melanoma. Clin Cancer Res 15(9):3029-36, 2009. e-Pub 2009. PMID: 19383818.
153. O'Reilly KE, Warycha M, Davies MA, Rodrik V, Zhou XK, Yee H, Polsky D, Pavlick AC, Rosen N, Bhardwaj N, Mills G, Osman I. Phosphorylated 4E-BP1 Is Associated with Poor Survival in Melanoma. Clin Cancer Res 15(8):2872-2878, 2009. e-Pub 2009. PMID: 19336517.
154. Davies MA, Stemke-Hale K, Tellez C, Calderone TL, Deng W, Prieto VG, Lazar AJ, Gershenwald JE, Mills GB. A novel AKT3 mutation in melanoma tumours and cell lines. Brit J Cancer 99(8):1265-1268, 2008. PMID: 18813315.
155. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies MA, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero V, Gray JW, Bernards R, Mills GB, Hennessy BT. An integrative genomic and proteomic analysis of PIK3CA, PTEN and AKT mutations in breast cancer. Cancer Res 68(15):6084-91, 2008. PMID: 18676830.
156. Koul D, Jasser SA, Lu Y, Davies MA, Shen R, Shi Y, Mills GB, Yung WK. Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity. Oncogene 21(15):2357-2364, 2002. PMID: 11948419.
157. Davies MA, Kim SJ, Parikh NU, Dong Z, Bucana CD, Gallick GE. Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells. Clin Cancer Res 8(6):1904-1914, 2002. PMID: 12060635.
158. Koul D, Parthasarathy R, Shen R, Davies MA, Jasser SA, Chintala SK, Rao JS, Sun Y, Benvenisite EN, Liu TJ, Yung WK. Suppression of matrix metalloproteinase-2 gene expression and invasion in human glioma cells by MMAC/PTEN. Oncogene 20(46):6669-78, 2001. PMID: 11709701.
159. Beresford SA, Davies MA, Gallick GE, Donato NJ. Differential effects of phosphatidylinositol-3/Akt-kinase inhibition on apoptotic sensitization to cytokines in LNCaP and PCc-3 prostate cancer cells. J Interferon Cytokine Res 21(5):313-22, 2001. PMID: 11429162.
160. Tanaka M, Koul D, Davies MA, Liebert M, Steck PA, Grossman HB. MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells. Oncogene 19(47):5406-5412, 2000. PMID: 11103942.
161. Lu Y, Lin YZ, LaPushin R, Cuevas B, Fang X, Yu SX, Davies MA, Khan H, Furui T, Mao M, Zinner R, Hung MC, Steck P, Siminovitch K, Mills GB. The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. Oncogene 18(50):7034-45, 1999. PMID: 10597304.
162. Davies MA, Koul D, Dhesi H, Berman R, McDonnell TJ, McConkey D, Yung WK, Steck PA. Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. Cancer Res 59(11):2551-6, 1999. PMID: 10363971.
163. Delehedde M, Cho SH, Sarkiss M, Brisbay S, Davies MA, El-Naggar AK, McDonnell TJ. Altered expression of bcl-2 family member proteins in nonmelanoma skin cancer. Cancer 85(7):1514-22, 1999. PMID: 10193941.
164. Davies MA, Lu Y, Sano T, Fang X, Tang P, LaPushin R, Koul D, Bookstein R, Stokoe D, Yung WK, Mills GB, Steck PA. Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis. Cancer Res 58(23):5285-90, 1998. PMID: 9850049.
165. Miglierina R. Some applications of microspheres in flow cytometry. Biol Cell 58(2):127-30, 1986. PMID: 2950951.
166. Tripp MK, Gershenwald JE, Davies MA, Garcia J, Gritz ER, Hawk ET, Peterson SK. Assessment of Compliance With Texas Legislation Banning Indoor UV Tanning by Minors. JAMA Dermatol. e-Pub 2016. PMID: 27829081.
167. Vettus E, Draper D, Davies MA. Metastatic Melanoma Responding to Combination Chemotherapy and Immunotherapy After Progression on Ipilimumab and Nivolumab Immunotherapy. Annals of Clinical Case Reports. e-Pub 2017.
168. Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Chen PL, Beird HC, Garber HR, Roh W, Wani K, Chen E, Haymaker C, Forget MA, Little LD, Gumbs C, Thornton RL, Hudgens CW, Chen WS, Austin-Breneman J, Sloane RS, Nezi L, Cogdill AP, Bernatchez C, Roszik J, Hwu P, Woodman SE, Chin L, Tawbi H, Davies MA, Gershenwald JE, Amaria RN, Glitza IC, Diab A, Patel SP, Hu J, Lee JE, Grimm EA, Tetzlaff MT, Lazar AJ, Wistuba II, Clise-Dwyer K, Carter BW, Zhang J, Futreal PA, Sharma P, Allison JP, Cooper ZA, Wargo JA. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genom Med 2. e-Pub 2017. PMID: 28819565.
169. Vera-Aguilera J, Bedikian AY, Bassett RL, Hwu WJ, Kim KB, Qin Y, Cain S, Washington EW, Davies MA, Patel SM, Homsi J, Papadopoulos NE, Hwu P, Patel SP. Phase I/II Study of Hepatic Arterial Infusion of Nab-paclitaxel in Patients With Metastatic Melanoma to the Liver. Am J Clin Oncol. e-Pub 2018. PMID: 29509591.

Invited Articles

1. Davies MA, Flaherty KT. Melanoma in 2017: Moving treatments earlier to move further forwards. Nat Rev Clin Oncol 15(2):75-76, 2018. e-Pub 2017. PMID: 29182162.
2. Fischer GM, Vashisht Gopal YN, McQuade JL, Peng W, DeBerardinis RJ, Davies MA. Metabolic Strategies of Melanoma Cells: Mechanisms, Interactions with the Tumor Microenvironment, and Therapeutic Implications. Pigment Cell Melanoma Res 31(1):11-30, 2018. e-Pub 2017. PMID: 29049843.
3. Davies MA, Saiag P, Long GV. Primary medical therapy for BRAFV600E-mutant melanoma brain metastases—is this good enough?. The Lancet Oncology 18(9):1137-1284, 2017.
4. Glitza Oliva I, Tawbi H, Davies MA. Melanoma brain metastases: current areas of investigation and future directions. Cancer J 23(1):68-74, 2017. PMID: 28114258.
5. Loghavi S, Routbort MJ, Patel KP, Luthra R, Wang WL, Broaddus RR, Davies MA, Lazar AJ. How Do We Make Clinical Molecular Testing for Cancer Standard of Care for Pathology Departments?. J Natl Compr Canc Netw 14(6):787-92, 2016. PMID: 27283170.
6. Davies MA. Molecular Approaches to Tumor Inhibition in Melanoma. Clinical Advances in Hematology & Oncology 13(12), 2015. PMID: 27058849.
7. Davies MA. Role and complexity of next-generation sequencing in melanoma. Cancer Cytopathol 123(6):329-30, 2015. e-Pub 2015. PMID: 25877344.
8. McQuade J, Davies MA. Converting biology into clinical benefit: lessons learned from BRAF inhibitors. Melanoma Manag 2(3):241-254, 2015. PMID: 26594316.
9. Glitza IC, Davies MA. Genotyping of Cutaneous Melanoma. Chin Clin Oncol 3(3):27, 2014. PMID: 25632386.
10. Chen G, Davies MA. Targeted Therapy Resistance Mechanisms and Therapeutic Implications in Melanoma. Hematology/Oncology Clinics of North America 28(3):523-536, 2014. PMID: 24880945.
11. Shtivelman E, Davies MA, Hwu P, Yang J, Lotem M, Oren M, Flaherty KT, Fisher DE. Pathways and therapeutic targets in melanoma. Oncotarget 5(7):1701-52, 2014. e-Pub 2014. PMID: 24743024.
12. Bucheit AD, Davies MA. Emerging insights into resistance to BRAF inhibitors in melanoma. Biochem Pharmacol 87(3):381-9, 2014. e-Pub 2013. PMID: 24291778.
13. Davies MA. Targeted Therapy for Cutaneous Melanoma: Beyond. J Patient-Centered Res Rev 1(1):12-20, 2014.
14. Kwong LN, Davies MA. Navigating the Therapeutic Complexity of PI3K Pathway Inhibition in Melanoma. Clin Cancer Res 19(19):5310-9, 2013. PMID: 24089444.
15. Kwong LN, Davies MA. Targeted Therapy for Melanoma: Rational Combinatorial Approaches. Oncogene, 2013. e-Pub 2013. PMID: 23416974.
16. Davies MA. The Role of the PI3K-AKT Pathway in Melanoma. Cancer J 18(2):142-7, 2012. PMID: 22453015.
17. Woodman SE, Lazar AJ, Aldape KD, Davies MA. New Strategies in Melanoma: Molecular Testing in Advanced Disease. Clin Cancer Res 18(5):1195-200, 2012. e-Pub 2012. PMID: 22275506.
18. Davies MA. Targeted Therapy for Brain Metastases. Adv Pharmacol 65:109-42, 2012. PMID: 22959025.
19. Davies MA. Regulation, Role, and Targeting of AKT in Cancer. J Clin Oncol 29(35):4715-7, 2011. e-Pub 2011. PMID: 22025159.
20. Chen G, Davies MA. Emerging insights into the molecular biology of brain metastases. Biochem Pharmacol 3:305-14, 2011. e-Pub 2011. PMID: 21946085.
21. Davies MA, Gershenwald JE. Targeted therapy for melanoma - A primer. Surg Oncol Clin N Am 20(1):165-80, 2011. e-Pub 2011. PMID: 21111965.
22. Davies MA, Samuels Y. Analysis of the genome to personalize therapy for melanoma. Oncogene 29(41):5545-55, 2010. e-Pub 2010. PMID: 20697348.
23. Woodman SE,Davies MA. Targeting KIT in Melanoma: A Paradigm of Molecular Medicine and Targeted Therapeutics. Biochem Pharmacol 80(5):568-74, 2010. e-Pub 2010. PMID: 20457136.
24. Davies MA, Hennessy B, Mills GB. Point mutations of protein kinases and individualised cancer therapy. Expert Opin Pharmacother 7(16):2243-61, 2006. PMID: 17059381.
25. Davies MA. Metastatic renal cell carcinoma: new standards for first-line therapy?. Molecular Oncology Report, 2006.

Editorials

1. McQuade JL, Daniel CR, Hess KR, Davies MA. Sex as a predictor of response to cancer immunotherapy. Lancet Oncology 19(8):376, 2018. PMID: 30102226.
2. Davies MA. BRAF in early stage melanoma: rationale for testing and treatment?. Br J Dermatol 173(1):9-10, 2015. PMID: 26174638.
3. Davies MA. Finding the Right Balance of BRAF Inhibition in Melanoma. Cancer Discov 4(5):510-2, 2014. PMID: 24795008.
4. Davies MA, Kopetz S. Overcoming Resistance to MAPK Pathway Inhibitors. J Natl Cancer Inst 105(1):9-10, 2013. PMID: 23250957.
5. Davies MA. Special Issue on Melanoma. Cancer J 18(2):115-6, 2012. PMID: 22453010.

Abstracts

1. Yennu Nanda VG, Gammon S, Prasad R, Knighton B, Pisaneschi F, Feng N, Williams L, Pramanik S, Sudderth J, Sui D, Fischer GM, Deng W, Peng W, Wang J, McQuade JL, Tetzlaff M, Di Francesco ME, Marszalek J, Piwnica-Worms D, DeBerardinis RJ, Davies MA. A novel mitochondrial inhibitor overcomes resistance to BRAF and MEK inhibition in melanoma. 2019 Melanoma Research Alliance 11th Annual Scientific Retreat, 2019.
2. Fischer GM, Kotrotsou A, Ahmed S, O'Neal P, Sahnoune I, Yennu-Nanda VG, Hudgens C, Knighton B, Colen R, Tetzlaff MT, Davies MA. Molecular, immunological, metabolic, and radiomic associations of oxidative phosphorylation (OXPHOS) in melanoma brain metastases (MBMs). AACR Special Conference on Melanoma: From Biology to Target, 2019.
3. Nagarajan P, Piao J, Ning J, Noordenbos LE, Curry JL, Torres-Cabala CA, Diwan AH, Aung PA, Ivan D, Ross MI, Royal RE, Wargo JA, Wang WL, Samdani R, Lazar AJ, Rashid A, Davies MA, Prieto VG, Gershenwald JE. Prognostic Model for Disease Specific Survival in Anorectal Melanoma. AACR Special Conference on Melanoma: From Biology to Target, 2019.
4. Carapeto FCL, Fischer GM, Joon AY, Chen H, Haydu L, Lee S, Saul M, Appana S, Thompson JF, Mann GJ, McQuade JL, Lazar AJ, Kirkwood J, Scolyer RA, Long GV, Davies MA. Analysis of molecular and immune features that correlate with serum lactate dehydrogenase (LDH) levels in patients (pts) with metastatic melanoma. AACR Special Conference on Melanoma: From Biology to Target, 2019.
5. Andrews MC, Chen S, Prieto P, Marszalek J, Hudgens C, Tetzlaff MT, Amaria R, Gershewald J, Davies MA, Arur S, Heffernan TP, Wargo J. Sexual dimorphism in response to BRAF mut melanoma target therapy. 2018 SMR International Congress Meeting, 2018.
6. Fischer GM, Yennu-Nanda VG, Tetzlaff MT, Lazar AJ, Carapeto F, de Macedo MP, Hudgens C, Holmen SL, Kircher DA, Knighton B, Davies MA. Oxidative Phosphorylation (OXPHOS): A Feature, Driver, and Therapeutic Target in Melanoma Brain Metastases (MBMs). 2018 SMR International Congress Meeting, 2018.
7. McQuade JL, Gopalakrishnan V, Spencer C, Andrews MC, Helmink B, Cogdill AP, Sirmans E, Haydu LE, Posada E, Burton E, Glitza I, Amaria R, Patel S, Diab A, Wong M, Tawbi HA, Hwu WJ, Davies MA, Hwu P, Jenq R, Nelson K, Daniel CR, Cohen L, Wargo J. The gut microbiome of melanoma patients is distinct from that of healthy individuals and is impacted by probiotic and antibiotic use. 2018 SMR International Congress Meeting, 2018.
8. Reddy S. Helmink B, Zhang S, Blando J, Han G, Amaria R, Tawbi HA, Davies MA, Hwu P, Lee J, Gershenwald J, Burton E, Hudgens C, Keung E, Gaudreau P, Gopalakrishnan V, Reuben A, Andrews MC, Spencer C, Allison J, Sharma P, Tetzlaff MT, Wang L, Wargo J. B cell signature predicts survival in melanoma and response to immune checkpoint blockade (ICB). 2018 SMR International Congress Meeting, 2018.
9. Tiago M, Capparelli C, Erkes D, Purwin TD, Davies MA, Aplin AE. BET proteins inhibition to optimize BRAFi/MEKi therapy for mutant BRAF melanoma. 2018 SMR Congress International Meeting, 2018.
10. Glitza IC, Rohlfs ML, Iqbal M, Ricahrd J, Burton E, Duncan S, Brown C, Anderson J, Hwu P, Hwu WJ, Yee C, Patel S, Woodman S, Amaria R, Diab A, Tawbi H, Davies MA. A phase I/Ib study of concurrent intravenous (IV) and intrathecal (IT) nivolumab (Nivo) For melanoma patients (pts) with leptomeningeal disease (LMD). ESMO 2018 Congress International, 2018.
11. McQuade, JL, BetofWarner A, Li M, Chon J, Haydu LE, Daniel-MacDougall Carrie, Hess KR, Johnson DB, Menzies AM, Davies, Shoushtari AN. Association of body mass index (BMI) with overall survival (OS) in metastatic melanoma (MM) patients (pts) treated with combined anti-CTLA4 + anti-PD1. ASCO Annual Meeting 2018, 2018.
12. Peng W, Xu Chunyu, Melendez B, Jackson H, McKenzi JA, Williams LJ, Chen Y, Mbofung RM, Leahey SE, Lizee G, Davies MA, Yanamandra N, Hwu P. OX40 agonist antibody-based combination therapy with PI3Kβ selective inhibitor enhances T cell immunity. AACR Annual Meeting 2018, 2018.
13. de Macedo PM, Wang F, Marzese DM, Hudges CW, Wani K, Haydu LE, Danaher P, Merritt C, Ong G, Warren S, Beechem JM, Hoon DSB, Peng W, Kwong L, Tetzlaff MT, Lazar AJ, Davies MA. In-depth Molecular and Immune Characterization of Melanomas with Heterogeneous PTEN Expression. Society of Immunotherapy of Cancer, 2017.
14. de Macedo MP, Wang F, Marzese DM, Hudgens CW, Wani K, Siroy AE, Haydu LE, Danaher P, Merritt C, Ong G, Warren S, Beechem JM, Hoon DSB, Peng W, Tetzlaff M, Lazar A, Davies MA. In-depth molecular and immune characterization of melanoma with heterogeneous PTEN expression. World Congress for Melanoma, 2017.
15. Schadendorf D, Long GV. Grog JJ, Nathan P, Ribas A, Davies MA, Flaherty KT, Squires M, Jaeger S, Powell W, Tan P Robert C. PD-L1 and CD8 expression and association with outcomes in patients (pts) with BRAF V600E/K–mutant metastatic melanoma (MM) who received dabrafenib + trametinib (D+T) in the randomized phase 3 COMBI-v study. ASCO Annual Meeting 2017, 2017.
16. Davies MA, Robert C, Long GV, Grob JJ, Flaherty KT, Arance A, Sileni-Chiarion V, Thomas L, Lesimple T, Mortier L, Moschos S, Hogg D, Rodas IM, Del Vecchio M, Lebbe C, Meyer N, Zhang Y, Huang Y, Mookerjee B, Saiag P. COMBI-MB: a phase 2 study of combination dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600–mutant (mut) melanoma brain metastases (MBM). ASCO Annual Meeting 2017, 2017.
17. Chen WS, Andrews MC, Spencer C, Tawbi HAH, Lazar A, Tetzlaff MT, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Amaria RN, Burton EM, Woodman SE, Davies MA, Gershenwald JE, Sharma P, Allison JP, Futreal A, Wargo JA,. Molecular and immune predictors of response and toxicity to combined CTLA-4 and PD-1 blockade in metastatic melanoma (MM) patients (pts). ASCO Annual Meeting 2017, 2017.
18. Janku F, De Groot JF, Javle MM, Prado-Penas M, Shroff RT, Luthra R, Banks K, Lanman RB, Conley AP, Broaddus R, Davies MA, Kopetz S, Yung WKA, Heymach J, Fu S, Shaw KR, Meric-Bernstam F. Simultaneous molecular alterations in solid tumors with IDH1 or IDH2 mutations. ASCO Annual Meeting 2017, 2017.
19. Wargo JA, Gopalakrishnan V, Spencer C, Karpinets T, Reuben A, andrews MC, Tetzlaff MT, Lazar M, Hwu P, Hwu WJ, Clitza IC, Tawbi HAH, Patel SP, Lee JE, Davies MA, Gershenwald JE, Futreal A, Sharma P, Allison JP, Jenq RR. Diversity and composition of the gut microbiome are associated with enhanced responses and improved progression-free survival (PFS) in metastatic melanoma (MM) patients (pts) on anti-PD-1 therapy. ASCO Annual Meeting 2017, 2017.
20. Wargo JA, Amaria RN, Prieto PA, Andrews MC, Tetzlaff MT, Futreal PA, Hwu P, Hwu WJ, Glitza IC, Tawbi HAH, Cormier JN, Lee JE, Patel SP, Simpson L, Burton EM, Bassett RL Jr., Ross MI, Gershenwald JE, Davies MA, Woodman SE. Treatment with neoadjuvant and adjuvant dabrafenib + trametinib (D+T) compared to standard-of-care (SOC) surgery and to identify targets to enhance responses in patients (pts) with high-risk resectable BRAF-mutant metastatic melanoma. ASCO Annual Meeting 2017, 2017.
21. McKean MA, Haydu LE, Ma J, Bssett RL Jr., Hwu WJ, Patel, SP, Diab A, Glitza IC, Tawbi HAH, Wong MK, McQuade JL, Hwu P, Davies MA, Amaria RN. Prognostic factors for overall survival (OS) in metastatic melanoma (MM) treated with immune checkpoint inhibitors: A single institution study of 696 patients. ASCO Annual Meeting 2017, 2017.
22. Menzies AM, Rozeman EA, Amaria RN, Scolyer RA, Tetzlaff MT, Guminski A, Davies MA, Blank CU, Wargo JA, Long GV. Preliminary results from the international neoadjuvant melanoma consortium (INMC). ASCO Annual Meeting 2017, 2017.
23. Schvartsman G, Ma J, Bassett RL Jr., Haydu LE, Amaria RN, Hwu P, Hwu WJ, Diab A, Patel SP, Davies MA, Tawbi HAH. Incidence, patterns of progression and outcomes of melanoma brain metastasis (MBM) during programmed-death 1 inhibitor (PD1i) therapy. ASCO Annual Meeting 2017, 2017.
24. Patel SP, Glitza IC, Diab A, Amari RN, Davies MA, Hwu P, Tawbi HAH, Hwu WJ. The safety and early efficacy of high-dose ipilimumab (IPI) and the combination nivolumab plus ipilimumab (NIVO + IPI) in patients (pts) with uveal melanoma (UM). ASCO Annual Meeting 2017, 2017.
25. Maria, RN, Prieto P, Tetzlaff M, Diab A, Patel S, Woodman SE, Hwu WJ, Glitza IC, Hwu P, Tawbi H, McQuade JL, Cormier J, Lucci A, Royal R, Lee J, Bassett R, Simpson L, Burton EM, Grimm EA, Reuben A, Spencer C, Gershenwald JE, Ross M, Davies MA, Wargo JA. Treatment with neoadjuvant + adjuvant dabrafenib and trametinib (D+T) is associated with imporoved relapse-free survival (RFS versus standard of care (SOC) therapy in ptients with high-risk resectable BRAF-mutant melanoma. 2016 SMR Congress, 2016.
26. Bindal S, Ferguson S, Davies MA, Haydu L, Basset R JR, McCutcheon I, Glitza IC. Leptomeningeal disease (LMD) from metastatic melanoma: a single institution experience and predictors of survival. 2016 SMR Congress, 2016.
27. Capparelli, Purwin TJ, Davies MA, Aplin AE. Stromal neuregulin-1 modulates the response to MEK inhibitors in WT BRAF/WT NRAS (WT/WT) melanoma. 2016 SMR Congress, 2016.
28. Cheng H, Chua V, Purwin TJ, Terai M, Liao C Kageyama K, Davies MA, Sato T, Aplin AE. Co-targeting HGF0cMET signaling with MEK inhibitors in metastatic uveal melanoma. 2016 SMR Congress, 2016.
29. McQuade JL, Wang DY, Rai R, Park J, Spencer C, McKean M, Beckermann K, Nahar K, Rubinstein S, Guminski A, Lo S, Sosman JA, Wargo JA, Daniel C, Long GV, Hwu P Hess K, Carlin MS, Menzies A, Johnson DB, Davies MA. High body mass index (BMI) is associated with improved clinical outcomes in metastatic melanoma patients treated with anti-PD1: differences by gender. 2016 SMR Congress, 2016.
30. Long DV, FLaherty KT, Schadendorf D, Nathan P, Robert C, Ribas A, Davies MA, Lane S, Legos JJ, Mookerjee B, Grob JJ. Patients characteristics associated with >36-mo clinical benefit with combination dabrafenib and trametinib (D+T) in COMBI-d. 2016 SMR Congress, 2016.
31. Teh, Jessica NIkbakht N, Purwin TJ, Chervoneva I, Davies MA, Aplin AA,. In vivo E2F reporting on efficacious dosing schedule MEK plus CDK inhibition in melanoma. 2016 SMR Congress, 2016.
32. Long GV, Flaherty KT, Schadendorf D, Nathan P, Robert C, Ribas A, Davies MA, Lane S, Legos J, Mookerjee B, Grob JJ. Patient Characteristics Associated With ≥ 36-month Clinical Benefit With Combination Dabrafenib and Trametinib in COMBI-d. ESMO 2016 Scientific, 2016.
33. Menzies AM, Johnson DB, Ramanujam S, Atkinson V, Wond ANM, Parker JJ, McQuade JL Shoushtari AN, Tsai KK, Eroglu Z, Klein O, Hassel JC, Sosman JA, Guminski A, Sullivan RJ, Ribas A, Carlin MS, Davies MA, Sandhu SK, Long GV. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders (AD) or major toxicity with ipilimumab (IPI). ASCO Annual Meeting 2016, 2016.
34. Flaherty K, Davies MA, Grob JJ, Long DV, Nathan PD, Ribas A, Robert C, Schadendorf D, Frederick DT, Hammond MR, Valbuena-Jane J, Mu XJ, Squires M, Jaeger SA, Lane ST, Mookerjee B, Garraway LA. Genomic analysis and 3-y efficacy and safety update of COMBI-d: A phase 3 study of dabrafenib (D) + trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma. ASCO Annual Meeting 2016, 2016.
35. Shaw AC, Trinh V, Bassett RL, Glitza IC, Diab A, Amaria RN, Tawbi HAH, Davies MA, Hwu WJ, Hwu P, Patel SP,. Retrospective analysis of safety and efficacy of ipilimumab in elderly patients with advanced melanoma. ASCO Annual Meeting 2016, 2016.
36. Barcena E, Trinh V, McIntyre SE, Simien R, Cain S, Diab A, Amaria RN, Patel SP, Glitza IC, Tawbi HAH, Davies MA, Hwu WJ. Responses in patients with BRAF V600-mutant metastatic melanoma receiving anti-PD1/PDL1 therapy alone or combined with BRAF inhibitors. ASCO Annual Meeting 2016, 2016.
37. Kim DW, Haydu LE, Joon A, Bassett RL, Siroy A, Tetzlaff MT, Lazar A, Woodman SE, Gershenwald JE, Davies MA,. Pathological and clinical features of non-acral cutaneous melanoma (CM) patients (pts) with TP53 and BRAFnon-V600 (NonV600) mutations (muts). ASCO Annual Meeting 2016, 2016.
38. McQuade JL, Haydu LE, Frankian S, Spencer C, Long GV, Brob JJ, Lane SR, Legenne P, Flaherty K, Hwu P, Hess KR, Davies MA. The impact of obesity on outcomes in metastatic melanoma (MM) patients (pts) treated with dabrafenib and trametinib. ASCO Annual Meeting 2016, 2016.
39. Rohlfs, M, Bassett RL, Lacey C, McQual N, Mehta U, John I, Simien R, Tupue S, Dett TK, Glitza IC, Diab A, Amaria RN, Tawbi HAH, Davies MA, Hwu WJ, Hwu P, Patel SP. BRAF with or without MEK inhibition plus PD-1 checkpoin blockade for the treatment of metastatic melanoma. ASCO Annual Meeting 2016, 2016.
40. Grob JJ, Flaherty K, Long GV, Nathan PD, Schadendorf D, Ribas A, Robert C, Lane SR, Mak C, Legenne P, Davies MA. Pooled aanalysis of safety over time and link between adverse events and efficacy across combination dabrafenib and trametinib (D+T) registration trials. ASCO Annual Meeting 2016, 2016.
41. Amaria RN, Haymaker CL, Bernatchez C, Forget MA, Patel V, Hwu WJ, Davies MA, Patel SP, Diab A, Glitza IC, Tawbi HAH, Woodman SE, Wargo JA, Ross MI, Lee JE, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Hwu P. A phase I/II study of lymphodepletion plus adoptive cell transfer (ACT) with T cells transduced with CXCR2 and NGFR followed by high dose interleukin-2 (IL-2) in patients with metastatic melanoma (MM). ASCO Annual Meeting 2016, 2016.
42. Sullivan RJ, Barbash Z, Edelheit O, Vidne M, Sosman JA, Flaherty K, Davies MA, Johnson DB, Tarcic G. Functional characterization of non-V600 BRAF mutations and their response to Trametinib (Tram). ASCO Annual Meeting 2016, 2016.
43. Patel SP, L S, Rohlfs ML, Fox PS, Richard J, Iqbal M, Bernzen T, Glitza IC, Papdopoulos NE, Hwu P, Davies MA. BRAF and NRAS mutations in Metastatic Melanoma Patients with Leptomeningeal Disease. ASCO Annual Meeting 2015, 2015.
44. Oba J, Wang WL, Eterovic AK, Stephan CC, Roszik J, Kale CR, Haymaker CL, Routbort M, Haydu LE, Bernatchez C, Davies MA, Lazar AJF, Grimm EA, Woodman SE,. A global genomic and small molecule inhibitor interrogation of KIT mutant melanoma to reveal underlying biology and novel molecular targets. ASCO Annual Meeting 2015, 2015.
45. Roszik J, Joon A, Siroy A, Haydu LE, Stingo F, Baladandayuthapani V, Hwu P, Tetzlaff MT, Wargo JA, Chen JQ, Laszlo GR, Bernatchez C, Gershenwald JE, Lazar AJF,Davies MA, Woodman SE. A novel algorithm applicable to cancer next-generation sequencing panels to predict total tumor mutation load and correlation with clinical outcomes in melanoma. ASCO Annual Meeting 2015, 2015.
46. Haydu LE, Calderone TL, Miller J, Bassett RL, Joon A, Zhang J, Morgan MB, Shaw KR, Cooper ZA, Burton EM, Siroy A, Wani KM, Stingo F, Baladandayuthapani V, Tetzlaff MT, Wargo JA, Lazar AJF,Davies MA, Gershenwald JE,. Comparison of DNA and RNA analyte extraction and melanin removal methods from formalin-fixed parraffin-embedded (FFPE) melanoma. ASCO Annual Meeting 2015, 2015.
47. Davies MA, Joon A, Bassett RL, Roszik J, Siroy A, Haydu LE, Chen K, Stingo F, Baladandayuthapani V, Shaw KR, Meric-Bernstam F, Tetzlaff MT, Gershenwald JE, Woodman SE, Lazar AJF,. Demographics, tumor characteristics, and clinical outcomes associated with somatic mutations in 201 cancer-related genes in advanced melanoma patients (pts). ASCO Annual Meeting 2015, 2015.
48. Bedard PL, Davies MA, Kopetz S, Flaherty KT, Shapiro G, Luke JJ, Spreafico A, Wu B, Gomez C, Cartot-Cotton S, Mazuir F, Micallef S, Demers B, Juric D,. First-in-human phase I trial of the PI3Kb-selective inhibitor SAR260301 in patients with advanced solid tumors (NCT01673737). ASCO Annual Meeting 2015, 2015.
49. Kemnade J, Roszik J, Joon A, Stingo F, Baladandayuthapani V, Lazar AJF, Woodman SE, Davies MA. Identification of potentially actionable mutations in RTKs in melanoma detected by next generation sequencing (NGS). ASCO Annual Meeting 2015, 2015.
50. Wargo JA, Amaria RN, Ross MI, Saw RPM, Gershenwald JE, Hwu P, Patel SP, Glitza IC, Diab A, Kefford R, Scolyer RA, Rizos H, Thompson JF, Shannon K, Spillane A, Carlino MS, Guminski A, Simpson L, Davies MA, Long GV. Neoadjuvant BRAF (dabrafenib) and MEK (trametinib) inhibition for high-risk resectable stage III and IV melanoma. ASCO Annual Meeting 2015, 2015.
51. Amaria RN, Bassett RL, Simpson L, Delaney F, Hwu P, Kim K, Hwu WJ, Patel SP, Glitza IC, Davies MA, Woodman SE, Yee C, Bedikian AY,. Phase I study of ipilimumab (IPI) with biochemotherapy (BCT) for chemonaïve patients with metastatic melanoma (MM). ASCO Annual Meeting 2015, 2015.
52. Diab A, Martin A, Simpson L, Algazi AP, Chawla P, Kim DW, Santra S, Patel V, Jadhav N, Abhyankar D, Davies MA, Buch SC, Kim K, Daud A. Phase I trial of the CDK 4/6 inhibitor, P1446A-05 (voruciclib) in combination with the BRAF inhibitor (BRAFi), vemurafenib in advanced, BRAF-mutant melanoma. ASCO Annual Meeting 2015, 2015.
53. McQuade JL, Chen G, Panka DJ, Reuben A, Bassett RL, Joon A, Lazar AJF, Tetzlaff MT, Simpson L, Mouton R, Patel SP, Glitza IC, Hwu WJ, Amaria RN, Diab A, Hwu P, Wargo JA, Sullivan RJ, Kim K, Davies MA. Phase II study of dabrafenib and trametinib following progression on BRAF inhibitor monotherapy in metastaticmelanoma: Exploration of clinical and molecular predictors of response. ASCO Annual Meeting 2015, 2015.
54. Meric-Bernstam F, Brusco L, Daniels MS, Strong LC, Shaw KR, Lu KH, Qi Y, Lara-Guerra H, Litton JK, Zhao H, Eterovic AK, Arun B, Routbort M, Janku F, Davies MA, Kopetz S, Mendelsohn J, Mills GB, Chen K. Prevalence of incidental actionable germline mutations in 1,000 advanced cancer patients on a prospective somatic genomic profiling program. ASCO Annual Meeting 2015, 2015.
55. Amaria RN, Wargo JA, Cooper ZA, Tetzlaff MT, Reuben A, Davies MA, Gershenwald JE, Jiang H, Austin-Breneman J, Lee JE, Hwu P, Hwu WJ, Cormier JN, Royal RE, Lucci A, Patel SP, Diab A, Glitza IC, Burton EM, Ross MI. Treatment with neoadjuvant BRAF Inhibition Yields Responses in Patients (pts) with High Risk Borderline Resectable Stage III Melanoma. ASCO Annual Meeting 2015, 2015.
56. Joon A, Haydu L, Baladandayuthapani V, Stingo F, Woodman S, Amaria A, Wargo J, shaw K, Meric-Bernstam F, Mills G, Gershenwald J, Hwu P, Lazar a, Davies MA. Next generation sequencing of 201 cancer-related genes in melanoma. Society for Melanoma Research 2014 Congress, 2014.
57. Davies MA, Tawbi H, Ouellet D, Lazar AJF, Weinberg JS, Butterfiels LH, Hamilton RL, Amankulor N, Engh JA, Shivlingham B, Kefford R, Scoyer GV, Mahmood S, Richards-Peterson LE, Swann S, Arbushites MC, Long GV, Kirkwood JM. Pharmacokinetic and pharmacodynamic analysis of preoperative therapy with dabrafenib alone and in combination with trametinib in patients with BRAF mutation–positive melanoma with metastases to the brain (BRV116521). ASCO Annual Meeting 2014, 2014.
58. Glitza IC, Bernatchez C, Bassett RL, Vaughn C, Velasquez P, Diab A, Amaria RN, Yee C, Woodman SE, Patel SP, Kim KB, Davies MA, Papadopoulos NE, Bedikian AY, Hwu WJ, Radvanyi LG, Hwu P. Treatment with tumor-infiltrating lymphocytes (TIL) in metastatic melanoma and clinical benefit regardless of site of origin, mutation status, or prior checkpoint blockade. ASCO Annual Meeting 2014, 2014.
59. Davies MA, Martins KD, Sessa T, Swann S. Phase II, open-label study of dabrafenib plus trametinib in patients with BRAF mutation-positive melanoma brain metastases: A GSK-sponsored trial. ASCO Annual Meeting 2014, 2014.
60. Yorio JT, Bucheit AD, McIntyre S, Fox P, Bassett R, Davies MA. Toxicities and outcomes in metastatic melanoma patients (pts) treated with Ipilimumab (Ipi) and BRAF inhibitors (BRAFi). Society for Melanoma Research Meeting, 2013.
61. Bucheit AD, Joseph RW, Milton D, Fox P, BAssett R, Gershenwald JE, Tetzlaff MT, Prieto VG, Lazar AJ, Davies MA. PTEN loss correlates with shorter time to brain metastasis and overall survival in stage IIIB/C melanoma patients. 2013 ESMO, 2013.
62. Stockman D, Tetzlaff MT, Al-Zaid T, Torres-Cabala CA, Bucheit AD, Lazar AJF, Sui D, Jakob JA, Bassett R, Prieto VG, Davies MA, Curry JL. Differential clinical associations of BRAF and NRAS mutations among histologic types of cutaneous melanomas. ASCO Annual Meeting 2013 31, 2013.
63. Chen G, Kim SB, Lazar AJ, Stemke-Hale K, Deng W, Lee JS, Davies MA. Characterization of point mutations and copy number changes in melanoma patients with matched brain and extracranial metastases. 2012 SMR Congress, 2012.
64. Yennu Nanda VG, Komurov K, Patel LR, Chen G, Ram PT, Guichard S, Smith PD, Davies MA. The dual MTOR inhibitor AZD8055 synergizes with MEK inhibition in a metabolically unique subset of MEK inhibitor-resistant melanomas. 2012 SMR Congress, 2012.
65. Koay EJ, Bucheit AD, Jakob JA, Hyun ED, Settle SH, Brown PD, Davies MA, Sulman EP,. Correlation of BRAF and NRAS mutation status with tumor characteristics and treatment outcomes in melanoma patients with brain metastasis. ASCO Annual Meeting 2012, 2012.
66. Kirkwood JM, Long GV, Trefzer, Davies MA, Ascierto PA, Chapman PB, Puzanov I, Hauschild A, Robert C, Kefford R, Goodman VL, Switzky JC, Swann RS, Martin AM, Guckert ME, Streit MRW, Schandendorf D. BREAK-MB: a Phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600 E/K mutation-positive melanoma with brain metastases (mets). ASCO Annual Meeting 2012, 2012.
67. Mu H, Calderone TL, Davies MA, Prieto V, Wang H, Mills GB, Bar-Eli M, Gershenwald JE. Lysophosphatidic Acid Induces Lymphangiogenesis and Interleukin-8 Production in Human Lymphatic Endothelial Cells. Am J Pathol 180(5):2170-81, 2012. e-Pub 2012. PMID: 22465753.
68. Davies MA. Molecular and clinical correlates of PTEN expression in melanoma. AACR Annual Meeting 2012, 2012.
69. Yennu Nanda VG, Overwijk WW, Davies MA, Gelbard A, Van Dyke MW. Parthenolide induces in vivo anticancer activity through its atypical regulation of HDAC1 and MDM2, leading to p53 activation, Era of Hope 2011. Congressionally Directed Medical Research Programs, 2011.
70. Patel SP, Bedikian AY, Papadopoulos NE, Hwu WJ, Kim KB, Homsi J, Davies MA, Woodman SE, Radvanyi LG, Woodard K, Mahoney S, Hwu P. Ipilmumab plus temozolomide in metastatic melanoma. 2011 ASCO Annual Meeting, 2011.
71. Jakob JA, Bassett RL, Ng CS, Lazar AJF, Alvarado GC, Rohlfs ML, Richard J, Gershenwald JE, Hwu P, Kim KB, Davies MA. Clinical characteristics and outcomes associated with BRAF and NRAS mutations in metastatic melanoma. 2011 ASCO Annual Meeting, 2011.
72. Joseph RW, Hwu P, Davies MA, Atkins MB, Sullivan RJ. Clinical benefit of ipilmumab in patients with metastatic melanoma who progress on high dose IL-2. 2011 ASCO Annual Meeting, 2011.
73. Pravinkumar SE, Nigam R, Hwu P, Davies MA, Price K. Intensive care unit resource utilization for high dose interleukin-2 therapy: A 3-year experience from a large oncologic ICU. 2011 Canadian Respiratory Conference, 2011.
74. Joseph RW, Sullivan RJ, Panka D, Manoukian G, Percy A, Harrell R, Bassett RL, Atkins MB, Hwu P, Davies MA. Effect of mutational status on response, PFS, or OS after the treatment with IL-2 for metastatic melanoma. 2010 ASCO Annual Meeting, 2010.
75. Davies MA, Lee JS. Integrated Analysis of Phospho-Proteins and Gene Expression Profiles Identifies P-GSK3 as a Critical Node in Melanoma. 2009 S.M.R. International Congress Meeting, 2009.
76. Davies MA, Gershenwald JE. Integrated Analysis of Kinase Signaling Pathways in Melanoma Clinical Specimens. 2009 NCI Translational Meeting, 2009.
77. Davies MA, Stemke-Hale K, Calderone T, Deng W, Lazar A, Prieto VG, Aldape K, Mills GB, Gershenwald JE. Quantitative assessment of AKT activation in melanoma. ASCO Annual Meeting, 2009.
78. Woodman SE, Trent JC, Stemke-Hale K, Lazar A, Pricl S, Pavan GM, Papadopoulos N, Hwu P, Mills GB, Davies MA. Selective Activity of Dasatinib for the Most Common KIT Mutation in Melanoma (L576P). ASCO Annual Meeting, 2009.
79. Kim KB, Davies MA, Papadopoulos NE, Bedikian AY, Hwu W, Woodard K, Washington EW, Dancey JE, Wright J, Hwu P. Phase I/II study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. ASCO Annual Meeting, 2009.
80. *Vasudevan KM, *Barbie DA, *Davies MA, Rabinovsky R, Hennessy BT, Tseng H, Pochanard P, Kim SY, Dunn IF, Schinzel AC, McNear CJ, Kim J, Boehm JS, Silver S, Lu Y, Stemke-Hale K, Joy C, Sahin AA, Gonzalez-Angulo AM, Lluch A, Rameh LE, Jacks T, Root DE, Lander ES, Mills GB, Hahn WC, Sellers WR, Garraway LA (*contributed equally). PDK1-SGK3 signaling in the absence of AKT activation in PIK3CA-mutant cancers. 2009 AACR Annual Meeting, 2009.
81. Yordy JS, Byers LA, Davies MA, Mills G, Ju Z, Ang KK, Heymach JV. Protein Expression Profiling Identifies Markers of Radiation Sensitivity and Resistance in the NCI 60 Cell Lines. ASCO-NCI-EORTC Annual Meeting, 2008.
82. Yordy JS, Byers LA, Davies MA, Molkentine D, Raju U, Mills G, Minna J, Coombes K, Ang KK, Heymach JV. Reverse Phase Protein Arrays Reveal Biomarkers of Radiation Resistance in Head & Neck and Lung Cancer Cell Lines. Translational Advances in Radiation Oncology and Cancer Imaging Symposium, 2008.
83. Davies MA, Vasudevan KM, Hennessy BT, Rabinovsky R, Stemke-Hale K, Tseng H, Dutta B, Garraway LA, Mills GB. AKT-independent, PDK1-dependent signaling by oncogenic PIK3CA mutations. AACR Translational Cancer Medicine, 2008.
84. Hwu WJ, Ivan D, Prieto VG, Simon J, Jones D, Ekmekcioglu S, Davies MA, Ayala AE, Garcia ME, Ross M. Randomized phase II neoadjuvant study of temozolomide (TMZ) alone or with pegylated interferon-alfa 2b (PGI) in patients with resectable AJCC stage IIIC or stage IV (M1a) metastatic melanoma. ASCO Annual Meeting, 2008.
85. Kopetz ES, Wu J, Davies MA, Parikh N, Johnson F, Gallick G, and Donato N. Synergistic activity of Src and EGFR inhibitors in colon cancer. AACR Annual Meeting, 2007.
86. Kopetz S, Wu J, Davies MA, Johnson F, and Donato N. Synergistic effects of combination therapy with anti-EGFR and anti-Src therapy in vitro in colon cancer. ASCO Gastrointestinal Cancers Symposium, 2007.
87. Davies MA, Bedikian AY, McIntyre S, Smith T, Kim K, Hwu W, Papadopoulos N, and Hwu P. Natural history of melanoma patients with CNS metastases. ASCO Annual Meeting, 2006.

Book Chapters

1. Siroy AE, Davies MA , Lazar AJ. The PI3K-AKT Pathway in Melanoma. In: Genetics of Melanoma. Cancer Genetics: New York, 165-180, 2016.
2. Glitza IC, Heimberger AB, Sulman EP, Davies MA. Prognostic factors for survival in melanoma patients with brain. In: Brain Metastases from Primary Tumors. Academic Press: New York, 267-297, 2016.
3. Davies MA. Parallel and Serial Blockade Strategies in BRAF-Mutant Melanoma. In: BRAF Targets in Melanoma. Humana Press: Maryland, 105.135, 2015.
4. Davies MA, Garraway LA. Molecular Biology of Cutaneous Melanoma. In: Cancer Principles & Practice of Oncology. 10th. Wolters Kluwer, 1337-1345, 2015.
5. Davies MA, Garraway LA. Molecular Biology of Cutaneous Melanoma. In: Cancer: Principles and Practice of Oncology. Primer of the molecular biology of cancer. 2nd edition. Wolters Kluwer, 308 - 320, 2015.
6. Kupferman ME, Davies MA. Melanoma of the Head and Neck: General Principles and Management. In: Head and Neck Cancer A Multidisciplinary Approach. 4th. Wolters Kluwer Lippincott Williams & Wilkins, 672-691, 2013.
7. Ahmed KB, Davies MA. New Molecular Targets for Systemic Therapy of Melanoma. In: Research on Melanoma - A Glimpse into Current Directions and Future Trends,. InTech - Open Access Publisher, 161-180, 2011.
8. Kim KB, Davies MA, Rapini RP, Hwu P, Bedikian AY. Malignant Melanoma. In: The MD Anderson Manual of Medical Oncology, Second Edition. 2nd. McGraw Hill: China, 1077-1109, 2011.
9. Davies MA, Patel S, Kim K. Targeted Therapy in Melanoma. In: Targeted Therapy in Cancer. 1. Humana Press: Totowa, NJ, 183-211, 2008.
10. Davies MA. PTEN, a tumor suppressor gene frequently mutated in glioblastomas. In: Genomic and Molecular Neuro-Oncology. Jones and Bartlett: Sudbury, MA, 47-61, 2004.